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I. Summary 
1. Introduction 
1.1 Autoantibodies and Autoantigens 
Autoantibodies are antibodies directed towards self antigens and found in 
autoimmune diseases. It is not certain whether all autoantibodies are 
pathogenic but many have been confirmed to be involved in the development of 
autoimmune diseases (Bizzaro, 2007). Independent of their role in 
pathogenesis they are useful for diagnostic purposes. 
It has become clear that in addition to knowing full-length antigens that are 
related to a certain autoimmune disease, the ability to accurately characterize 
an epitope structure on an antigen is essential to better understand the 
pathogenesis of such a disease (Dhungana et al., 2009; Raska et al., 2003) or 
to improve the diagnostic accuracy of an assay. 
Epitopes that are recognized by autoantibodies are structurally diverse, ranging 
from linear peptide sequences to quaternary structures, and can be modified, 
hidden, or even mimicked by other structures (Pollard, 2006). 
The determination of the amino acid sequence of epitope-containing peptides is 
of major interest in broad areas of biochemical and biomedical research, as it 
possesses the potential to define subsets of peptides indicative for marker auto-
antibodies of autoimmune diseases (Lorenz et al., 2009; Reichert et al., 2005). 
Knowledge of individual epitope patterns may eventually be suitable for 
stratification of patients, possibly leading to guidance for individualized therapy 
as well as for proteomics and protein characterization studies (Raska et al., 
2003). 
1.1.1 RA33 autoantigen 
The RA33 nuclear antigen is found in rheumatoid arthritis (RA) which is one of 
the most significant autoimmune diseases affecting 1-2% of the human 
population. More than 10% of the affected individuals encounter a severe fast 
progressing course of the disease (Steiner et al., 1996). RA is a chronic 
inflammatory and highly destructive joint disease characterized by persistent 
synovial inflammation, cartilage degradation, and bone erosion. The 
characteristics of RA33 nuclear antigen have been partly but not fully elucidated 
and work is in progress to unveil its nature. It is of interest that antiRA33 
antibodies may appear shortly after the onset of RA and are often detectable 
before a final diagnosis can be made. Therefore they can provide diagnostic 
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help in early disease, particularly when rheumatoid factor is negative; in a single 
case, the presence of the antibody in plasma even preceded disease symptoms 
by approximately one year (Steiner et al., 1996). So far, it has not been known 
which regions of RA33 are recognized by autoantibodies (Skriner et al., 1997). 
1.1.2 Fibrillarin autoantigen 
Fibrillarin; a 34-kDa auto-antigen; is present in all nucleated cell types and 
derives its name from its localization to both the fibrillar center (FC) and dense 
fibrillar component (DFC) of the nucleolus (Ochs RL, 1985). Fibrillarin is a target 
for the spontaneously arising autoantibodies in systemic sclerosis autoimmune 
disease (Ssc; scleroderma) which is a rare, chronic disorder characterized by 
degenerative changes and scarring in the skin, joints, and internal organs and 
by blood vessel abnormalities (Takeuchi et al., 1995). 
1.2 Protein structure characterization using mass spectrometry 
Mass spectrometric technologies enable profiling of autoantibody responses 
using biological fluids derived from patients with autoimmune disease 
(discussed in chapter III). They provide a powerful tool to characterize auto-
reactive B-cell responses in diseases including RA, multiple sclerosis, 
autoimmune diabetes, and systemic lupus erythematosus (SLE). Autoantibody 
profiling may serve purposes including classification of individual patients and 
subsets of patients based on their ‘autoantibody fingerprint’, examination of 
epitope spreading and antibody isotype usage, discovery and characterization 
of candidate autoantigens, and tailoring antigen-specific therapy.  
The advantages of mass spectrometric sample analysis are high sensitivity, 
high mass accuracy, rapid analysis time and low sample consumption (Hager-
Braun and Tomer, 2005). Presently, most mass spectrometers routinely allow 
analysis of peptides or proteins in the low femtomole level. 
1.2.1 Peptide mapping / Peptide mass fingerprint 
Protein structures can be characterized by mass spectrometric peptide mapping. 
This means, proteins are digested with specific proteases and their peptide 
fragments are characterized and identified by different mass spectrometric 
techniques, with or without chromatographic peptide separation prior to the 
mass spectrometric analysis (Bantscheff and Glocker, 2001). Amino acid 
sequences of known proteins can be recalled from public databases and 
subjected to software programs like GPMAW (Lighthouse Data, Odense, 
Denmark). These programs theoretically digest the protein and calculate the 
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apparent masses of the peptide fragments, generated by cleavage of a distinct 
protease in the according consensus sequence. By comparison of the apparent 
masses to the experimental m/z values a protein sequence coverage can be 
clearly identified. A spectrum is called interpreted, when all dominant ion signals 
are assigned to either belonging to the protein of interest or to major 
contaminants in the sample. 
By contrast, a process called Peptide Mass Fingerprint (PMF) is using 
databases such as Swiss-Prot and TrEMBL (Mikkat et al., 2004; Sinz et al., 
2002) for the identification of unknown protein upon mass spectrometric 
analysis of its proteolytic fragments. Here, high sequence coverage is not 
needed and the origin of many ion signals in the spectrum mostly is not 
identified as long as the identification result is unambiguous. 
1.2.2 MS peptide sequencing 
In cases of doubt, MS/MS fragmentation gives detailed information about the 
sequence and/or structure, i.e. post-translational modification of the original 
peptide molecular ion, the precursor ion. Due to fragmentation mainly along the 
peptide backbone, valuable information about the peptide sequence and its 
post-translational modifications are readily investigated. Fragment ions arising 
from MS/MS measurement can be of various types, according to their cleavage 
along the peptide backbone or from the side chains. If after cleavage the charge 
stays on the N-terminal fragment, the ions are named A, B, or C ions, according 
to Roepstorff and Fohlmann (Figure 1). If the charge stays on the C-terminal 
fragment the ions are labeled X, Y", or Z' ions (Roepstorff and Fohlman, 1984). 
Ions of the Y"- and the B series dominate MS/MS spectra when collision 
induced fragmentation (CID) is applied. Upon electron transfer-induced 
dissociation (ETD), C and Z' ions are dominating the spectrum (Zubarev, 2003). 
 
Figure 1: Fragmentation rules for peptides according to Roepstorff and Fohlmann. 
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Software tools can calculate the apparent masses of the arising fragment ions 
from given peptide sequences, which can then be compared to the 
experimental m/z values and confirm the supposed peptide sequence. Within 
the Y" and B fragment ion series the mass differences between adjacent ions 
corresponds to one amino acid residue. After interpretation of the MS/MS 
spectrum of an unknown peptide (many times called "de-novo sequencing" 
(Johnson and Taylor, 2002)) with regard to mass differences, typical for masses 
of distinct amino acid residues, partial amino acid sequences can be obtained. 
This information combined with the mass of the peptide can be used for 
searching in databases (Graves and Haystead, 2002; Koy et al., 2003). In this 
case the experimentally determined sequence is matched to known sequences, 
which is by definition not a de-novo sequencing experiment. 
1.3 Epitope mapping and epitope prediction 
It is important to realize that the epitope nature of a set of amino acids can only 
be established if an immunoglobulin that is able to bind to it has been found. 
The immunoglobulin is then called a specific antibody for the antigen that 
harbours the epitope. By contrast, the antibody nature of an immunoglobulin 
defined by its paratope becomes apparent even without a complementary 
known epitope. This sometimes leads to confusion since antigens may possess 
many different epitopes, but an antibody cannot be specific for the multi-epitopic 
antigen as a whole but only for one of its epitopes (Van Regenmortel, 1998). 
One of the main purposes of identifying epitopes is to replace the epitope 
regions of intact antigen molecules by linear synthetic peptides that could be 
used as reagents for detecting anti-protein antibodies in an immunoassay 
(Leinikki  et al., 1993) or as immunogens for raising anti-peptide antibodies able 
to cross-react with the target protein (Muller, 1999). Further purposes are to 
develop synthetic peptide vaccines (Van Regenmortel, 2006) or in diagnostics 
of autoimmune diseases which guide personalized therapies for patients 
(Lorenz et al., 2009; El-Kased et al., 2010). However, as epitope mapping is 
difficult to achieve, many different computational-based prediction methods 
were developed and compared (Pellequer et al., 1991; Ponomarenko and Van 
Regenmortel, 2009). Unfortunately, none of them, even when used in 
combination, gave high rates of successful prediction (Odorico and Pellequer, 
2003; Blythe and Flower, 2005; Greenbaum et al., 2007). Unsuccessful epitope 
prediction may partly explain why, after several decades of intensive research 
efforts, no synthetic peptide vaccine has yet been developed (Hans  et al., 
2006).  
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Therefore; robust epitope mapping procedures are of tremendous importance 
for immunoassay development and production of protective peptide vaccines. 
1.3.1 Immuno-analytical methods for epitope mapping 
A protein can be cleaved chemically or enzymatically to generate various 
internal peptides. The number of peptides produced depends on whether the 
protein is cleaved completely; at many sites; or partially; at limited number of 
sites. Small numbers of large fragments are produced by limited proteolysis of 
native proteins. The large fragments are easily separated and purified by either 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) or high-performance 
liquid chromatography (HPLC). Proteolytic fragments separated by SDS-PAGE 
can be electroblotted to an immobilizing membrane and probed with the 
antibody. The antibody will recognize those fragments containing the epitope. 
Proteolytic enzymes with different substrate specificity can be used to perform 
limited digestion of a protein antigen, and antibody binding to the fragments can 
be analyzed by Western blot (discussed in chapters II and III). When the 
sequence of the protein is known, the origin of the proteolytic fragments is 
easily determined after HPLC separation by matrix-assisted laser desorption/ 
ionization time of flight mass spectrometry (MALDI ToF MS) analysis. A 
limitation to this procedure is that the denaturated protein and its proteolytic 
fragments bound to the immobilizing membrane may no longer contain the 
same assembled and structural antigenic determinants present in the native 
protein. This technique is not reliable to identify complex assembled epitopes 
but it is still useful to detect sequential epitopes, consisting of a specific amino 
acid sequence. Another limitation is the blotting success that depends on the 
length of the peptide. Shorter peptides are not always bound strong enough for 
reliable probing for antibody interaction (El-Kased et al., 2009). 
1.3.2 Epitope mapping using mass spectrometric analysis 
In the case of assembled epitopes, the combination of immuno-precipitation and 
limited proteolytic digestion of the protein antigen, followed by MALDI ToF MS 
can be used for determining the antibody-binding region. Proteolytic 
fragmentation for epitope mapping using MALDI ToF MS analysis can be useful 
for localization of the antibody-binding region. Another approach to epitope 
mapping is complete proteolytic digestion of the target protein (discussed in 
chapter IV).  
The choice of complete vs. limited proteolysis to localize epitopes depends on 
several factors. If the unknown region is relatively big, then a limited digest with 
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subsequent generation of large fragments is preferable. Large protein 
fragments are also more likely to maintain a more native-like conformation, 
which may be important for epitope identification. However, many proteins 
generate multiple products of partial cleavage following limited proteolytic 
fragmentation. The complex patterns produced by limited proteolysis can be 
difficult to interpret, making complete proteolytic cleavage advantageous. 
Complete proteolytic fragmentation is also instrumental when the goal is to 
localize a specific epitope to the smallest number of amino acid residues 
possible. Nowadays, the origin of the proteolytic fragments is easily identified 
using either electrospray ionization time of flight mass spectrometry (ESI ToF) 
(Rower et al., 2009); or MALDI ToF MS (Mazzoni et al., 2009; Bantscheff and 
Glocker, 2001). 
In order to obtain information on sequential and/or assembled epitopes, various 
approaches have been developed in conjunction with mass spectrometry. Fine 
epitope mapping could be achieved by this technique with microgram quantities 
of antibodies and in a short time compared to conventional mapping methods. 
Rapid developments in mass spectrometry in combination with the proteolytic 
digestion of antigen have opened new methods of epitope mapping (Macht et 
al., 1996; Parker et al., 1996; Suckau et al., 1990). The method is based on the 
fact that antibodies in general are very resistant to proteolytic digestion.  
Epitope excision 
In epitope excision the immobilized monoclonal antibody (mAb) is incubated 
with the whole antigen and the bound antigen is digested with a protease 
(Figure 2) (Suckau et al., 1990). In general the antibody prevents either 
proteolysis or chemical modification of sites of the antigen that are situated in 
the antibody binding pocket. An important feature of this approach is, because 
non-denaturing conditions are used, that the antigen retains its native 
conformation so that assembled epitopes can be determined; it also offers the 
possibility of determining epitopes which contain an enzymatic cleavage site. 
Epitope excision and direct identification of a single immune complex by mass 
spectrometry has shown to be a sensitive and rapid method of high molecular 
specificity in the analysis of protein antigens. However, so far almost always 
binary systems were studied, i.e. one antigen was complexed with one 
(monoclonal) antibody solely. 
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Figure 2: Summary of the epitope excision process. The antigen is bound to the immobilized 
antibody, followed by digestion with various proteases. Protease 1 and protease 2, 
which cleave the antigen at different sites, are used for the digestion. Unbound 
peptides are washed off the column and the affinity-bound peptides are analyzed 
using mass spectrometry (Dhungana et al., 2009). 
Recently, chemical cross-linking of proteins has been combined with mass 
spectrometric analysis of the created cross-linked products to study the function 
of a protein and allow the identification of interaction sites with its binding 
partners (Sinz, 2006; Sinz, 2010). This procedure seems in principle applicable 
for epitope mapping, when both, the antigen and the antibody, are readily 
degradable into small peptides and the cross-linked products are analysed. As 
for most antibodies this is not the case, when using commercially available 
proteases. Cleavable cross-linkers may be applied in combination with rigid 
denaturation, but then further work-up steps are needed prior to mass 
spectrometry, making the procedure difficult to apply outside of expert 
laboratories. 
Epitope extraction 
The epitope extraction technique, applied also in chapter IV, is the proteolytic 
digestion of the free antigen and presentation of the mixture of peptide 
fragments to the antibody (mostly a mAb), followed by isolation of the antibody-
peptide complex (Figure 3). The epitope and non-epitope fractions are analyzed 
by MALDI-MS, and the epitope sequences are identified directly (Hochleitner et 
al., 2000; Bílková et al., 2005). 
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Figure 3: Summary of the epitope extraction process. Protease 1 and protease 2, which 
cleave the antigen at different sites, are used to digest the antigen. The antigen 
digest is passed through separate columns containing immobilized antibody. The 
antigenic determinants of the antigen remain bound to the antibody, while the 
unbound peptides are washed off from the column. The affinity-bound peptides are 
analyzed using mass spectrometry (Dhungana et al., 2009).  
In both of the above mentioned cases, the peptides containing the epitopes are 
eluted from immobilized antibody by low pH buffer and analyzed by mass 
spectrometric peptide fingerprinting in a separate step. The high accuracy and 
sensitivity of mass spectrometers helps in identifying the peptides by molecular 
masses and/or peptide sequencing. Clearly, applying immuno-analytical 
methods coupled with mass spectrometry allows the identification of the epitope 
region. 
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2. Research objectives and overview of the thesis  
The aim of this study is to establish a robust, direct and easy method to 
characterize the epitope of an antibody. It will be shown that coupling mass 
spectrometry-derived findings with peptide chip analysis leads to a precise 
identification of the epitope peptide of a monoclonal antibody (chapter II) as well 
as of patients` sera (poly-/oligoclonal antibodies) (chapter III). The applied 
approach may lead to better stratification of patients, possibly leading to 
guidance for individualized therapy.  
Establishing a novel method for epitope mapping in solution, without 
immobilization of the antibody, using a manual micro-column size exclusion 
chromatography coupled with mass spectrometry is discussed in chapter IV as 
a simplified approach for epitope mapping. The new proposed method yielded 
in a consistent assignment of the epitope carrying peptide which was previously 
assigned using immuno-analytical methods combined with mass spectrometric 
analysis, as applied in chapter II.  
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3. Practical approach 
3.1 Epitope identification using immuno-analytical methods coupled with 
mass spectrometry 
RA33 was subjected to BrCN degradation with subsequent generation of large 
fragments because the epitope region was unknown. Using few cleavage sites 
enhances the chances to not disrupt the epitope. The produced fragments were 
separated on 1D SDS PAGE then the antibody binding to the fragments were 
analysed by Western blot; where fragments containing the epitope could be 
assigned to the RA33 protein sequence using mass spectrometry. RA33 
degraded with BrCN was also separated with HPLC then the antibody binding 
to fragments in the separated fractions were analysed by dot blot, where 
fragments containing the epitope could be assigned to the RA33 protein 
sequence using mass spectrometry. Both immuno-analytical experiments 
combined with mass spectrometry lead to the same assignment of the epitope 
on RA33 protein against which the mAb is directed (section 4.1). The epitope 
region was confined to the partial amino acid sequence aa 79-163 of the 
recombinant RA33 using this method. 
Using the peptide chip analysis method (section 3.2); synthetic peptides 
representing the whole RA33 amino acid sequence were synthesized as 15mer 
peptides overlapping by 9 amino acid residues each. Results obtained from this 
experiment showed that the epitope was SIDGRVVEP (amino acid range 84 -
 92). The results were in agreement with the results obtained from the immuno-
analytical methods. 
The application of immuno-analytical methods combined with mass 
spectrometry on detection of epitopes in patients` sera was investigated 
(chapter III). Poly-/oligoclonal antibodies presented by patients` sera were 
investigated for the epitope towards which they were directed on RA33. The 
same procedure as explained above was applied. Again the epitopes assigned 
by the immuno-analytical methods in combination with mass spectrometry were 
in good agreement with the peptide chip analysis assignment (section 4.2). 
3.2 Peptide chip analysis 
High density peptide microarray technologies can be applied in experimental 
medicine in general and in clinical immunology in particular. Any known 
sequence can serve as input to synthesize overlapping peptides in the search 
of disease-associated epitope profiles as preferentially found in sera of patients 
suffering from autoimmune diseases (Lorenz et al., 2009). The patterns of 
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bound primary antibodies from the sample are generally visualized using 
secondary anti-species IgG antibodies conjugated to fluorescence dyes. 
High density microarrays consisted of a peptide library spotted in triplicates as 3 
identical subarrays. 15mer overlapping peptides were derived from RA33 
autoantigen under investigation and for other proteins as well. One subarray 
carried a total of 9176 peptides from 95 known human autoantigens. These 
peptide microarrays were incubated with goat anti-species IgG Fab fragments 
conjugated to AlexaFluor647 (i.e. secondary antibody; Invitrogen) and scanned 
by a Molecular Device GenePix 4000B scanner. Primary data analysis is based 
on the scanned images and was performed with the GenePix Pro software. 
Intensities were ranging from 0 to 65536 after subtraction of the background. All 
data points were recorded in triplicate and data used for further interpretation 
are mean values. 
3.3 Epitope identification using manual size exclusion micro-column 
chromatography coupled with mass spectrometry 
Size exclusion chromatography (SEC) is particularly well suited for 
separation of proteins from smaller components because it provides easily 
interpretable qualitative information, i.e. the rough molecular weight 
distribution of a mixture consisting of such components (Sanny, 2002). In 
addition, SEC is run under non-denaturing conditions which allow the 
maintenance of the biological activity of the protein (here, the antibody). In 
SEC, separation is based primarily on size, and as a result, is not 
noticeably enhanced by the addition of mobile phase modifiers. Resolution 
in SEC is therefore essentially a sole function of separation efficiency 
(Lemmo and Jorgenson, 1993). Important developments in SEC have 
continued in the area of detection systems, mainly light scattering, viscometry, 
and MALDI ToF mass spectrometry in conjunction with SEC for determining 
molecular weights and chemical composition of polymeric materials (Barth et al., 
1998). Miniaturization of the column used in SEC separations to micro-column 
dimensions offers various advantages to the technique; such as low sample 
consumption, low cost per column and reduced maintenance requirements and 
short duration (Cortes and Pfeiffer, 1993).  
The antigens under investigation in this study were subjected to enzymatic 
proteolysis in order to obtain peptides of masses below 5000 Da. These 
peptides were subjected to SEC alone or after incubation with mAb in-solution. 
The epitope-containing peptide, when affinity bound to the antibody and, thus, 
forming a large complex, eluted early on separation with SEC leaving the 
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enzymatic cleavage products of the antigenic protein that did not contain the 
epitope and, hence, were small in size, behind to elute in late fractions. In 
chapter IV; this novel approach was applied using a manually fabricated micro-
column SEC. The approach was first established using two model systems 
(Fibrillarin and RA33 auto-antigens) containing a His-tag against which anti-His-
tag antibodies are directed. Afterwards the approach was applied on the RA33 
autoantigen against its mAb (studied in chapter II). 
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4. Results 
4.1 Epitope mapping of RA33 using mAb through coupling of mass 
spectrometry and immuno-analytical methods 
The aim of our study (chapter II) is to characterize the epitope of a monoclonal 
antiRA33 antibody on recombinant RA33 using mass spectrometric epitope 
mapping. Recombinant RA33 has been subjected to BrCN cleavage and 
fragments were separated by SDS PAGE. Subsequent in-gel proteolytic 
digestion and mass spectrometric analysis determined the partial sequences in 
the protein bands. Western blotting of SDS-PAGE-separated protein fragments 
revealed immuno-positive, i.e. epitope containing bands. BrCN-derived RA33 
fragments were also separated by HPLC and immuno-reactivity of peptides was 
measured by dot-blot analysis with the individual HPLC fractions after partial 
amino acid sequences were determined. The epitope range was confined to the 
partial amino acid sequence aa 79-163 of the recombinant RA33. The herewith 
identified epitope region was compared to data from peptide chip analyses with 
15-meric synthetic peptides attached to a glass surface. Results from all three 
analyses consistently showed that the epitope of the monoclonal anti-RA33 
antibody is located in region aa84–92 on recombinant RA33; the epitope 
sequence is (84SIDGRVVEP92) (El-Kased et al., 2009).  
4.2 Epitope mapping of RA33 autoantigen using sera from rheumatoid 
arthritis patients through coupling of mass spectrometry and 
immuno-analytical methods 
Mass spectrometric epitope mapping in combination with peptide chip analysis 
(chapter III) showed that autoantibodies from patients who suffered from 
rheumatoid arthritis (RA) were directed against distinct surface structures on the 
full-length human autoantigen RA33 as well as against partial sequences. Using 
the combined mass spectrometric epitope extraction and peptide chip analysis 
approach, four sequence motifs on RA33 emerged as immuno-positive, 
showing that epitopes were not randomly distributed on the entire RA33 amino 
acid sequence. A sequential epitope motif (245GYGGG249) was determined on 
the C-terminal part of RA33 which matched with the Western blot patient 
screening results using the full-length protein and, thus, was regarded as a 
disease-associated epitope. Other epitope motifs were found on N-terminal 
partial sequences (59RSRGFGF65, 111KKLFVG116) and again on the C-terminal 
part (266NQQPSNYG273) of RA33. As recognition of these latter three motifs was 
also recorded by peptide chip analysis using control samples which were 
negative in the Western blot screening, these latter motifs were regarded as 
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"cryptic epitopes". Again, mass spectrometry-derived results were in full 
agreement with the epitope chip data (El-Kased et al., 2010).  
4.3 Epitope mapping of proteins using manual size exclusion micro-
column chromatography  
4.3.1 Development of the in-solution epitope mapping procedure 
In order to develop the manual SEC for epitope mapping of antigens two 
epitopes, His-tags from recombinant proteins, were selected as model epitopes 
(chapter IV). Recombinant Fibrillarin, a protein derivative comprising amino acid 
range 76-321 of the full length protein and containing a His-tag at the N-
terminus, resulted only in partial degradation upon exposure to trypsin. 
Nevertheless, the generated peptide mixture was found to be suitable for 
continuing the experimental procedure as nearly full sequence coverage was 
obtained. SEC experiments of the peptide mixture after incubation with the anti-
His antibody showed that a peptide ion signal appeared in the early eluting 
fractions which was not found in the peptide mixture without incubation with the 
antibody. Mass spectrometric peptide sequencing analysis of this ion signal 
revealed its amino acid sequence as being the His-tag-containing N-terminal 
peptide (3GSHHHHHHGSYLGDTIESSTHASGK27), against which the anti-His 
antibody is directed. 
Using the same antibody, the same protease, and the same experimental 
procedure with a different protein, RA33, again a recombinant protein consisting 
of 314 amino acids including a His-tag at the N-terminus, we were able to 
identify a peptide ion signal which was present in the early eluting fractions 
when the tryptic peptide mixture was incubated with the anti-His antibody but 
was absent in those fractions in the absence of the antibody. Chemically 
assisted fragmentation-MALDI-MS (CAF-MALDI-MS) and subsequent MS/MS 
measurements were used to confirm the sequence assignment; where the 
epitope sequence is (1MSHHHHHHHHSMEREK16) (El-Kased et al., 2011).  
4.3.2 Application of in-solution epitope mapping procedure  
Thermolysin was the enzyme of choice for RA33 proteolysis as it produced 
peptides below 4000 Da for all sequence parts throughout the molecule 
(chapter IV). Comparing the fractions that eluted after SEC experiments of the 
peptides mixture in the absence of the mAb with those where the antibody was 
present, one peptide ion signal at m/z 1240.01 was observed which shifted from 
fraction 8 (late eluting in the absence of the antibody) to fraction 3 (early eluting 
in the presence of it). Together with all control experiments, this shift in elution 
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suggested that this peptide ion signal was representing the epitope to which the 
mAb was directed. Mass spectrometric measurements including MS/MS 
sequencing of this peptide ion signal at m/z 1240.01 revealed its amino acid 
sequence (85IDGRVVEPKRA95). This sequence is the same as previously 
assigned to being the epitope using the immuno-analytical methods coupled 
with mass spectrometry and peptide chip analysis (cf. chapter II) (El-Kased et 
al., 2011). 
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5. Discussion 
Several methods have been developed for mapping protein epitopes of mAbs, 
which involve competition assays (Kuroki, 2009), partial proteolysis (Dhungana 
et al., 2009), expressing fragments (Böttger and Böttger, 2009), peptide libraries 
(Reineke, 2009; Bongartz et al., 2009), mass spectrometry (MS) (Dhungana et 
al., 2009), structure resolution by nuclear magnetic resonance (Rosen and 
Anglister, 2009) and X-ray crystallography (Sundberg, 2009). Proteolytic 
fragmentation has been used by us (El-Kased et al., 2009) and others 
(Pacholczyk  and Sweadner 1997) for mapping protein epitopes of mAbs. 
In our study an epitope extraction approach was applied for the identification of 
the epitope on the RA33 autoantigen against which a commercially available 
mAb is directed. All three sets of independent experimental data (see above) 
yielded in consistent assignments of epitope carrying peptides, showing that 
epitopes which are determined by peptide chip analysis are matching with the 
epitope regions that are found on the full-length protein as well.  
Our approach that was making use of the epitope extraction procedure with 
sera from patients that contained poly-/oligoclonal (auto)antibodies in 
conjunction with analyzing immuno-response of patient sera with peptide chips 
and with the combined mass spectrometric epitope extraction procedure 
identified four major sequence motifs on RA33 emerging as immuno-positive, 
and hence, showing that epitopes were not randomly distributed on the entire 
RA33 amino acid sequence. 
Recently, it was suggested that antiRA33 autoantibodies in patients may be 
directed against different epitopes and that the recognition pattern was 
associated with the disease (Schett et al., 2009). Truncated recombinant RA33 
protein derivatives and RA33-derived synthetic peptides were tested with 
patient sera for immuno-positive reactions and lead to the conclusion that RA 
patients´ autoantibodies against RA33 recognized an assembled, i.e. a 
conformational epitope that was placed on domain II (Skriner et al., 1997). The 
presence of (auto)antibodies against sequential epitopes on RA33 in RA patient 
sera has as yet not been addressed. By contrast, it was suggested that 
antiRA33 autoantibodies from SLE patients were predominantly directed 
against a sequential, i.e. a linear epitope of RA33 comprising aa155-175 (Schett 
et al., 2009). Hence, characterizing the epitope recognition specificities of 
autoantibodies in addition to the determination of the presence of 
autoantibodies against full-length antigens in autoimmune patients´ sera is 
regarded to be extremely helpful to improve the diagnostic and even prognostic 
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value of a screening method which may guide individual therapy and on which 
therapy-related decisions may be based on. 
In our third approach we wished to develop a simplified method for assigning an 
epitope which would have several characteristics; the reaction would occur in 
solution which would avoid certain artefacts and be similar to the reaction of 
antibody and soluble antigens in many in vivo situations. From a practical 
standpoint the method should be easily applied with the instrumentation usually 
found in the average protein-analytical laboratory.  
As most antibody-epitope complexes are quite stable, size exclusion 
chromatography was thought to provide a rapid means for epitope assignment. 
The development of a method using manual size exclusion micro-column 
chromatography to assign the epitope was initiated in this study with two model 
systems composed of recombinant His-Tag-containing antigens in combination 
with a monoclonal anti-His-tag antibody. Later the method was extended to 
identify an epitope within the recombinant RA33 autoantigen against which a 
monoclonal antiRA33 antibody was directed.  
It should be noted that a purified antigen protein is not required for this 
procedure, because only peptides containing the antigenic determinant will bind 
to the antibody in the initial step. The epitope-containing fragment, affinity 
bound to the antibody and, thus, forming a complex which elutes early on SEC, 
will be separated efficiently from the other enzymatic cleavage products of the 
antigen protein not containing the epitope. The latter remain small in size and 
elute late. Dissociation of the antigen-antibody complex prior to mass 
spectrometric analysis is unnecessary because the affinity-bound epitope 
peptides are released during the MALDI matrix crystallization process. 
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1. Abstract 
The protein termed RA33 was determined to be one major autoantigen in 
Rheumatoid Arthritis patients and antiRA33 autoantibodies were found to 
appear shortly after onset of RA. They often are detectable before a final 
diagnosis can be made in the clinic. The aim of our study is to characterize the 
epitope of a monoclonal antiRA33 antibody on recombinant RA33 using mass 
spectrometric epitope mapping. Recombinant RA33 has been subjected to 
BrCN cleavage and fragments were separated by SDS PAGE. Subsequent in-
gel proteolytic digestion and mass spectrometric analysis determined the partial 
sequences in the protein bands. Western blotting of SDS PAGE-separated 
protein fragments revealed immuno-positive, i.e. epitope containing bands. 
BrCN-derived RA33 fragments were also separated by HPLC and immuno-
reactivity of peptides was measured by dot-blot analysis with the individual 
HPLC fractions after partial amino acid sequences were determined. The 
herewith identified epitope region was compared to data from peptide chip 
analysis with 15-meric synthetic peptides attached to a glass surface. Results 
from all three analyses consistently showed that the epitope of the monoclonal 
antiRA33 antibody is located in the region aa79–84 on recombinant RA33; the 
epitope sequence is MAARPHSIDGRVVEP. Sequence comparisons of the 15 
best scoring peptides from the peptide chip analysis revealed that the epitope 
can be separated into two adjacent binding parts. The N-terminal binding parts 
comprise the amino acid residues “DGR” resembling the general 
physicochemical properties “acidic/polar–small–basic”. The C-terminal binding 
spots contain the amino acid residues “VVE” with the motif “hydrophobic–gap–
acidic”. The matching epitope region that emerged from our analysis on both, 
the full-length protein and the 15-meric surface bound peptides suggests that 
peptide chips are indeed suitable tools for screening patterns of autoantibodies 
in patients suffering from autoimmune diseases.  
Keywords 
autoimmune diseases; RA33 autoantigen; monoclonal antibody; mass 
spectrometry; epitope mapping; peptide chip analysis  
Abbreviations 
aa: amino acid 
DHB: 2,5-dihydroxy benzoic acid;  
CHCA: -cyano-4-hydroxy cinnamic acid  
RA33: rheumatoid arthritis autoantigen 
TBS: TRIS buffered saline 
ACN: acetonitrile 
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2. Introduction 
Rheumatoid arthritis (RA) is one of the most significant chronic diseases 
affecting ca. 1 % of the human population. It is characterized by chronic 
inflammation of the synovial joints which leads to progressive joint erosions and 
eventually to disability1-3. Over the past years, several autoantibodies have 
been described in patients with RA (e.g. antiperinuclear factor antibodies, 
antikeratin antibodies, antiRA33 antibodies) but not all have been successfully 
incorporated into routine clinical practice4. From them, RA33 was determined to 
be one major autoantigen in RA patients, but patients with systemic lupus 
erythematosus (SLE) and mixed connective tissue disease (MCTD) have been 
found to also possess autoantibodies against RA33 to some extent. However, 
these latter diseases differ in their reactivities to other spliceosomal proteins. 
Therefore, it has been postulated that antiRA33 autoantibodies are not only 
valuable diagnostic markers but may also allow additional insights into the 
pathogenesis of rheumatic autoimmune diseases5. 
RA33 carries its name according to its migration behaviour in SDS PAGE and 
has been found to be identical to the protein named hnRNP A2/B1 (RefSeq 
Accessions NP_002128 and NP_112533; Uniprot Accession number P22626). 
HnRNP proteins are associated with pre-mRNAs in the nucleus in complex 4 
which forms part of the spliceosome6. They are involved in pre-mRNA 
processing and other aspects of mRNA metabolism and transport.  
It is of particular interest that antiRA33 autoantibodies may appear shortly after 
the onset of RA and are often detectable before a final diagnosis can be made 
in the clinic. It has been reported that the presence of antiRA33 antibodies may 
predict disease symptoms by one year5. Therefore they can provide diagnostic 
help early in disease, particularly when Rheumatoid Factor (RF) is negative in 
patient samples. In conjunction with anti-CCP antibody level determination, 
measuring antiRA33 autoantibody levels in RA patients and in other 
autoimmune patients has become important in particular for diagnosing RA in 
the absence of RF and for estimating severity of the disease6,7. Predicting 
severity of disease development is directing ongoing and future therapy. 
It has become clear that in addition to knowing full-length antigens that are 
related to a certain autoimmune disease, the ability to accurately characterize 
an epitope structure on an antigen is essential to better understand the 
pathogenesis of such a disease8,9. The determination of the amino acid 
sequence of epitope-containing peptides is of major interest in broad areas of 
biochemical and biomedical research, as it possesses the potential to define 
Eur. J. Mass Spectrom. (2009) 15, 747-759 
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subsets of peptides indicative for marker autoantibodies of autoimmune 
diseases10. Knowledge of individual epitope patterns may eventually be suitable 
for stratification of patients, possibly leading to guidance for individualized RA 
therapy.  
In our study an epitope extraction approach was applied for the identification of 
the epitope on RA33 against which a commercially available monoclonal 
antibody is directed. RA33 has been degraded by BrCN and fragments were 
isolated by SDS PAGE. The partial sequences in the protein bands were 
determined by subsequent in-gel proteolytic digestion and mass spectrometric 
analysis. Combination with Western blotting revealed these fragments which 
were immuno-positive, i.e. contained the epitope. In addition, we separated 
BrCN-derived RA33 fragments by HPLC and analyzed the immuno-reactivity of 
peptides by dot-blot analysis whose partial amino acid sequences first were 
determined by mass spectrometry in the individual HPLC fractions. At last, the 
antibody-epitope peptide interaction was characterized using surface-bound 15-
mer peptides on chips to which the antibody was administered. All three sets of 
independent experimental data yielded in consistent assignments of epitope 
carrying peptides, showing that epitopes determined by peptide chip analysis 
are matching with the epitope regions that are found on the full-length protein as 
well.  
 
3. Materials and Methods 
3.1 HPLC separation of RA33 and BrCN fragments 
Recombinant RA33 protein was purchased from Euroimmun AG, Luebeck, 
Germany. This autoantigen was dissolved in 50 mM sodium phosphate, pH 7.4; 
8 M urea; and 1000 mM sodium chloride with a final concentration of 
2.42 mg/ml. HPLC was performed to remove salt extents from the recombinant 
RA33 protein. The HP 1100 chromatography system (Agilent, Boeblingen, 
Germany) was used, equipped with an UltraSep ESD 300 PROT RP4S 
125 x 2 mm end-capped column. 100 μl of sample were loaded and flow rate 
was set to 0.5 ml/min. Solvent A consisted of 0.1 % TFA in water and solvent B 
was 0.1 % TFA in acetonitrile. The following gradient was applied: from 0 to 
20 % B in 55 min, then to 80 % B in 5 min, 20 % B was reached in 10 min. The 
protein-containing fraction was collected and lyophilized in a speed-vac 
concentrator (Savant Instruments, Holbrook, NY, USA). 
The BrCN-derived fragments of RA33 were separated using the HPLC system 
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as described above with a solvent gradient from 0 to 10 % B in 10 min, then to 
80 % B in 70 min, 80 % B was kept for 10 min, then 10 % B was reached in 
10 min. An UltraSep ES PEPTID 125 x 2 mm column was used and flow rate 
was set to 0.5 ml/min. The separated and purified fractions were collected in 
Eppendorf LowBind tubes and lyophilized. 
3.2 BrCN degradation of RA33 
For BrCN degradation, HPLC purified and lyophilized RA33 (ca. 100 μg) was re-
dissolved in 30 l of 80 % ACN/0.1 % TFA solution. 10 l of 5 M BrCN solution 
was added and incubated for 20 h at 25 °C in the dark11. The mixture of BrCN-
derived fragments was lyophilized. Samples containing BrCN-derived fragments 
of RA33 were subjected to mass spectrometry, to HPLC and to SDS PAGE, 
respectively. 
3.3 SDS PAGE analysis of BrCN fragments of RA33 and in-gel tryptic 
digest 
The lyophilized BrCN-derived fragments of RA33 were resuspended in 30 μl of 
an aqueous 80 % ACN/0,1 % TFA solution, then took 5 μl and mixed with 5 μl 
of a 2.5fold sample buffer containing 156 mM TRIS, 5 % SDS, 25 % glycerol, 
and 12,5 % 2-mercaptoethanol. This sample solution (10 μl) was loaded onto a 
4-20 % TRIS glycine gel, 1.0 mm x 15 well (Invitrogen, Karlsruhe, Germany). 
The Broad Range Marker (New England BioLabs, Frankfurt/Main, Germany) as 
well as the Ultralow Range Marker (Sigma, Munich, Germany) were used for 
determining apparent molecular masses of the protein bands. Gels were run in 
MOPS buffer (0.025 M MOPS, 0.025 M TRIS, 3.465 mM SDS, 1.025 mM EDTA) 
and using the Xcell SurelockTM MiniCell electrophoresis chamber (Invitrogen, 
Karlsruhe, Germany) at a constant voltage of 200 V for 30 min. Gels were fixed 
with a 50 % ethanol/10 % acetic acid/water solution and stained with colloidal 
Coomassie Brillant Blue G-25012. Protein bands were manually excised and gel 
plugs were subjected to in-gel digestion with trypsin (Promega, Madison, WI, 
USA) and Asp-N (Roche Diagnostics, Mannheim, Germany), respectively13. For 
every gel plug, 5 l of the enzyme solution dissolved in 1 ml of a TRIS/HCl 
solution (3 mM, pH 8.5) was added per well and incubated for 5 h at 37 °C. 
Peptide mixtures were extracted with 5 μl of an aqueous solution consisting of 
50 % ACN, 0.3 % TFA, and 5 mM N-octylglucopyranoside.  
3.4 Sample preparation for mass spectrometry 
Lyophylized intact RA33 from HPLC purification (ca. 3 nmol) was re-dissolved in 
80 % ACN/0.1 % TFA (30 μl), vigorously shaken for at least 10 min and 
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centrifuged for 5 min at 13,000 rpm, 25 °C. For molecular mass determination 
and for ISD measurements, 0.5 μl of protein solutions were prepared onto a 
stainless steel target applying ferulic acid (saturated solution in 1 ml of an 
aqueous ACN/0.1 % TFA 33/67 v/v) and DHB (12.5 mg/ml in 50 % ACN/0.1 % 
TFA), respectively, as matrices. 1 μl of the ferulic acid solution was pipetted 
onto the target, left there for some seconds and removed. 0.5 μl of the sample 
solution were spotted on the target and 0.5 μl of ferulic acid solution were added 
and mixed with the sample solution directly on the target. The mixture was then 
allowed to dry on air.  
For ISD measurements, 0.5 μl of the RA33 solution were pipetted onto the 
target. 1.0 μl of DHB solution (12.5 mg DHB dissolved in 1 ml 50 %ACN/0.1 % 
TFA) was added, mixed directly on the target and air-dried. For peptide mass 
fingerprinting, sample preparations were carried out on an AnchorChipTM 
600/384 target plate (Bruker Daltonik, Bremen, Germany) applying CHCA as 
matrix14. 
3.5 MALDI ToF mass spectrometry 
MALDI ToF MS measurements were performed using a Reflex III mass 
spectrometer (Bruker Daltonik, Bremen, Germany) equipped with the SCOUT 
source and operated in positive ion linear mode. MALDI was carried out utilizing 
a nitrogen pulsed laser (337 nm, 3-5 ns pulse width). A total of 400 laser shots 
were accumulated producing sum spectra ranging from m/z 4000-80,000. 
Spectra were externally calibrated using the commercially available Protein 
Calibration Standards I and II (Bruker Daltonik, Bremen, Germany). ISD was 
performed using the following parameters: IS1: 20.00 kV, IS2: 16.35 kV, Lens: 
9.8 kV, Reflector: 23 kV, mass range: m/z 1000-10,000. ISD spectra were 
calibrated using ISD signals from myoglobin (Sigma, Munich, Germany)15,16.  
The in-gel digested tryptic peptides and the BrCN mixtures were analyzed in 
positive ion reflector mode. Spectra were externally calibrated with a 
commercially available Peptide Calibration Standard (Bruker Daltonik, Bremen, 
Germany) and internally re-calibrated using peptide ion signals of known 
masses of BrCN fragments or selected peptide ion signals from trypsin auto-
proteolysis with the following masses: ([M+H]+ 842.51, [M+H]+ 1045.56, [M+H]+ 
2211.11, [M+H]+ 2807.39). Spectra were analyzed using both the FlexAnalysis 
2.4 and BioTools 3.0 programs (Bruker Daltonik, Bremen, Germany). 
3.6 MALDI QIT ToF MS/MS sequencing 
MS/MS spectra were acquired with an Axima MALDI QIT ToF mass 
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spectrometer (Shimadzu Biotech, Manchester, UK) in positive ion mode utilizing 
a nitrogen pulsed laser (337 nm, 3-5 ns peak-width full width half maximum, 
FWHM) and employing a three-dimensional quadrupole ion trap supplied by 
helium (pulsed flow gas) for collisional cooling and argon (collisional gas) to 
impose collisionally induced dissociation (CID)17,18. For MS/MS measurements 
0.5 μl of the DHB solution (0.005 g dissolved in 1 ml of an aqueous ACN/0.1 % 
TFA (33/67 v/v) solution were spotted onto an AnchorChipTM 400/384 target 
plate (Bruker Daltonik, Bremen, Germany). 0.5 μl of the digested peptide 
mixtures were added, mixed directly on the target and air-dried. Spectra were 
externally calibrated with a manually mixed peptide standard consisting of 
bradykinin (1-7) [M+H]+ 757.39, angiotensin II [M+H]+ 1046.53, angiotensin I 
[M+H]+ 1296.68, bombesin [M+H]+ 1619.81, N-acetyl renin substrate 
[M+H]+1800.93, ACTH (1-17) [M+H]+ 2093.08, ACTH (18-39) [M+H]+ 2465.19, 
somatostatin [M+H]+ 3147.46, insulin (oxidized beta chain) [M+H]+ 3494.64 as 
well as internally re-calibrated using known ion signals of the MS/MS spectrum. 
Further processing and analysis of the MS/MS spectra were performed with the 
LaunchpadTM software, version 2.7.1 (Shimadzu Biotech, Manchester, UK). 
3.7 Immunoanalytical Analysis with antiRA33 mAb 
For Western blot analysis 1D SDS PAGE was performed as described above 
with BrCN-derived fragments. Separated protein fragments were blotted onto a 
PVDF membrane (Immobilon, Millipore, Schwalbach, Germany) by semi-dry 
blotting for 60 min with a current of 1.2 mA/cm2. The membrane was cut into 
strips. Strips were blocked with 2 ml blocking buffer (TBS 5 % non-fat dry milk 
powder, 1 % BSA 0.02 % thimerosal) for 2 h. Then the monoclonal antibody 
(mouse antihnRNP-A2/B1, suspended in 0.01 M PBS, pH 7.4, 15 mM sodium 
azide, antibody concentration: ca. 1.5 mg/ml, Sigma, Munich, Germany) was 
diluted 1:1900 with blocking buffer. This antibody solution (2 ml per strip) was 
added to the strips after blocking and incubated over night at 4 °C. Washing 
(three times with 2 ml per strip with a buffer consisting of TBS, 0.05 % TWEEN 
20 (v/v), 0.1 % BSA (w/v), 0.02 % thimerosal (w/v)) was followed by secondary 
antibody reaction (biotin-SP-conjugated AffiniPure Goat Anti-Mouse IgG+IgM 
(H + L), freeze-dried powder rehydrated in 1.5 ml of water (antibody 
concentration: 1.1 mg/ml in 0.01 M sodium phosphate, 0.25 M sodium chloride, 
pH 7.6, Jackson Immuno Research Laboratories, Inc., West Grove, PA, 
USA/Dianova). For this purpose the secondary antibody solution was diluted 
1:20,000 with blocking buffer. 2 ml per strip were added and incubated for 1 h at 
room temperature. Another washing step and reaction with 2 ml per strip of a 
1:10,000 dilution with blocking buffer of a Peroxidase-conjugated Streptavidin 
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solution (freeze-dried powder rehydrated in 1 ml water (concentration: 1 mg/ml 
in 0.01 M sodium phosphate, 0.25 M sodium chloride, pH 7.6, Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA, USA/Dianova) was 
carried out for 1 h at room temperature. Detection was performed using the 
SuperSignal West Pico Chemiluminiscent substrate (Pierce/ThermoFisher 
Scientific, Bonn, Germany). 
Lyophilized HPLC fractions of BrCN-derived fragments of RA33 were re-
dissolved in 310 μl of a buffer containing 4 M urea, 1 % CHAPS, 8 mM DTT, 
and 0.25 % IPG buffer each and 100 μl per well were added onto a PVDF 
membrane using the MINIFOLD dot blotting device (Schleicher & Schuell/ 
Whatman, Dassel, Germany) together with intact RA33 (1 μl of the stock 
solution as delivered with a final concentration of 2.42 mg/ml, was mixed with 
309 μl of the same buffer) as a positive control and a blank (water) as a 
negative control. After the dot blot procedure, the membrane was taken out of 
the device and the blocking as well as the antibody incubation procedure was 
performed as described above. 
3.8 Peptide Chip Analysis with antiRA33 mAb 
Replitope™ high density microarrays were custom-made at JPT Peptide 
Technologies GmbH, Berlin, Germany. Their layout consisted of the whole 
peptide library spotted in triplicate as 3 identical subarrays. One subarray 
carried a total of 9176 different 15mer peptides overlapping by 9 amino acid 
residues that reflected the amino acid sequences of 95 known human 
autoantigens. Peptide sequences were included derived from the RA33 
autoantigen isoforms (heterogeneous nuclear ribonucleoprotein hnRNPA2/B1 
RefSeq Accessions NP_002128 and NP_112533 (P22626)) as well as from 
hnRNPA1 (RefSeq NP_002127, NP_112420 (P09651)) and hnRNPAB (RefSeq 
NP_112556, NP_004490 (Q99729)) proteins. Details on peptide synthesis, chip 
layout, staining, processing and evaluation have been described previously10. 
Here, the chips were used to characterize the epitope binding profiles of a 
monoclonal antibody against RA33 (mouse Ig2a antihnRNPA2/B1, Sigma 
R4653). Incubations with antibody solutions were done in a chamber formed by 
a 2-slide sandwich in duplicate. The incubation volume was 500 μl for each step. 
Primary and secondary antibody samples were dissolved in a buffer consisting 
of TBS (50 mM TRIS/HCl pH 7.4, 150 mM sodium chloride), 0.05 % Tween 20, 
and 0.1 % BSA and incubated for 4 h at room temperature. The final 
concentration of the antiRA33 antibody was 3.8 μg/ml. The secondary antibody 
was a polyclonal Fab-fragment goat IgG preparation directed against human 
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IgG and conjugated with AlexaFluor647 fluorescent dye (Invitrogen Molecular 
Probes Z25408) and was used at 0.8 μg/ml concentration. After each antibody 
incubation step the chips were washed with buffer; 3 times for 5 min, each. 
Fluorescence readings were acquired at 10 μm resolution with a scanner that 
was equipped with a 635 nm laser and a 532 nm laser for excitation (Axon 
Instruments GenePix 4000B, Molecular Devices; Ismaning, Germany). TIFF 
format images with a resolution of 2540 dpi at 16 bit depth were analyzed with 
GenePix Pro software version 4.0 (Molecular Devices) using the chip layout file 
(GenePix Array List GAL file) with spot-specific information. The median 
fluorescence and the respective background at 635 nm excitation of each 
feature were used to generate a list of signals specific for the peptides on the 
chip. An image depth of 16 bit means that each pixel can cover signal 
intensities representing a grey value distribution from 0 up to 65536. 
 
4. Results 
4.1 Structural characterization of recombinant RA33 
The recombinant RA33 protein under investigation is consistent with the human 
hnRNP A2/B1 protein (Acc. No. P22626) except for the N-terminal His-Tag 
(aa1-11) and a sequence gap at position aa 250 | aa251 (aa 240-279 in hnRNP 
A2/B1), resulting in a short RA33 form like the one that is known in mouse 
(hnRNP A2/B1 isoform 3; Acc. No. O88569). The sequence from the mouse 
protein hnRNP A2/B1 isoform 3 matches well with the sequence of the human 
protein except for a single amino acid exchange; N258S. The recombinant 
RA33 protein used in this study, hence, consists of 314 amino acids (Fig. 1), all 
resembling the sequence of the human protein and yields in a calculated mass 
of 34,132 Da. 
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Figure 1: Amino acid sequence of recombinant RA33. The protein sequence resembles the 
A2 isoform of RA33 (Acc. No. P22626) with a His-tag at the N-terminus (printed in 
italic letters). The triangle maps the position, where the A2 isoform of RA33 bears an 
additional sequence stretch of 40 amino acids that is lacking in the recombinant 
RA33. Methionine residues are underlined. The boxed region contains the epitope 
that is recognized by the monoclonal antiRA33 antibody. 
The protein sample reveals a strong band in SDS PAGE at apparent molecular 
mass of 33 kDa and other faint bands (truncated forms) at lower mass range 
(data not shown). Molecular mass determination of the HPLC-purified protein by 
MALDI ToF MS shows a singly charged molecular ion at m/z 34,166 and a 
small unassigned signal at m/z 22,812. This latter ion signal may result from a 
truncated RA33 form that has not been completely removed by HPLC (Fig. 2).  
 
Figure 2: Linear MALDI ToF mass spectrum of HPLC purified recombinant RA33. A strong 
signal is observed for the singly charged molecular ion at m/z 34,166 (calculated Mr: 
34,132). A small unidentified signal is seen at m/z 22,812 (n.i.: not identified). Matrix: 
Ferulic acid.  
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As the C-terminal end of the recombinant RA33 amino acid sequence was 
hardly determinable by peptide mass fingerprinting (data not shown), in-source 
decay (ISD) measurements were performed using the Reflex III MALDI ToF 
mass spectrometer. The mass range in which fragment ions were observed 
(m/z 1000–8000) showed a nearly complete partial sequence from aa 234-305 
(Fig. 3). In the sequence gaps occurred at residues Asn253-Tyr254, at Pro269-
Ser270, and at Gly298-Gly299-Ser300, respectively. This observation is 
consistent with previous ISD analysis of other proteins19,20.  
 
Figure 3: MALDI ToF ISD spectrum of HPLC purified recombinant RA33. Fragment ion 
signals are recorded in the mass range of m/z 1000 to 8000. The ion signals cover 
the C-terminal sequence from aa 234 to aa 305. In the sequence gaps occurred at 
residues Asn253-Tyr254 at Pro269-Ser270, and at Gly298-Gly299-Ser300, 
respectively. Z+2 ions are labeled. Matrix: DHB.  
Combining all partial sequence information of peptide mapping experiments 
after digests using trypsin and Asp-N as well as the ISD measurements, we 
obtained sequence coverage of 98.4 % of the recombinant RA33 protein. Such 
high sequence coverage is presenting an appreciable starting position for 
assigning epitope regions as missing of ion signals for specific peptides in the 
mass spectrum certainly was disadvantageous for epitope determination, 
particularly when the epitope region was concerned. 
4.2 BrCN degradation of recombinant RA33 and subsequent SDS PAGE 
and Western blot analysis of the fragment mixture with monoclonal 
antiRA33 antibody 
HPLC purified recombinant RA33 was degraded by BrCN and the resulting 
fragment mixture showed no signals for intact recombinant RA33 in linear 
MALDI ToF mass spectra indicating complete degradation. Consistently, all 
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bands observed in SDS PAGE analysis of the BrCN-derived fragments were of 
lower apparent molecular masses than the intact full length RA33 mass (below 
33 kDa; Fig. 4A, lane 2). Bands could be visualized down to an apparent mass 
of 3.4 kDa. However, below the 10 kDa mark bands were quite diffuse, making 
the estimation of apparent masses difficult. The MALDI ToF MS mixture 
analysis of the BrCN-derived fragments yielded in more precise mass 
estimations of the ion signals in the mass range between 2 and 10 kDa. All 
observed ion signals resulted in nearly complete sequence coverage of 
recombinant RA33 (Table 1). Fragments predominantly possessed C-terminal 
homo-Ser lactone residues. 
Protein fragments containing bands 1 to 13 were blotted onto a PVDF 
membrane and subjected to Western blot analysis using a monoclonal 
antiRA33 antibody. Bands 1 to 9 were immuno-positive, thus, containing the 
epitope against which the monoclonal antiRA33 antibody is directed (Fig. 4B, 
lane 1). The smallest BrCN-derived fragment that stained positive was observed 
at apparent molecular mass of ca. 12 kDa (band 9 in Figs 4A and 4B). The 
largest non-immuno-positive band migrated with an apparent molecular mass of 
ca. 8 kDa (band 10 in Fig. 4A). Full-length RA33 protein (prior to HPLC) served 
as positive control, both, for SDS PAGE (Fig. 4A, lane 1) and for Western blot 
analysis (Fig. 4B, lane 2). As has been described above, non-HPLC purified 
samples of RA33 showed a strong band at an apparent mass of 33 kDa 
accompanied with faint bands for truncated forms. These truncated forms of 
RA33 also stained with the monoclonal antiRA33 antibody in the Western blot 
analysis.  
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Figure 4: SDS PAGE and Western Blot analysis of BrCN-derived fragments of recombinant 
RA33. The SDS PAGE image is aligned to the matching Western Blot image. A: 1D 
SDS PAGE. Lane 1: Full-length RA33. Lane 2: Bands of BrCN-derived fragments of 
RA33. B: Western Blot analysis. Lane 1: Immuno-positive bands due to the reaction 
of the BrCN-derived fragments with the monoclonal antiRA33 antibody. Lane 2: Full 
length protein. Bands of BrCN-derived fragments are numbered beginning from the 
top. Numbering of immuno-positive bands is printed in bold letters. Molecular mass 
marker positions are indicated on the left (numbers refer to apparent masses in kDa). 
For partial sequence assignments of BrCN-derived fragments of recombinant RA33 
see Table 2. 
In-gel trypsin digest of the BrCN-derived fragments in bands 1 to 13 from the 
Coomassie-stained SDS gel allowed estimation of sequence ranges of the 
respective BrCN-derived fragments; at least of the dominant fractions in a band 
when several fragments with similar masses overlapped (Supplemental Table 
1). In addition to the sequence coverage, our special interest was focused on 
the determination of possible end-groups of BrCN-derived fragments. Guided by 
the mixture analysis (Table 1), we searched for such peptides which were 
cleaved by BrCN on the one side and by trypsin on the other. Using this 
information on identified end groups together with the determined apparent 
molecular masses from the SDS PAGE runs enabled the estimation of the 
partial sequence ranges of the BrCN-derived fragment(s) in each band. 
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Table 1: MALDI MS analysis of BrCN-derived fragment mixture of RA33. 
Sequence Range Exp. Mass (m/z) Calc. Mass [M+H]+; (Da) 
13 - 52 4814 a,b) 4814.5 c) 
53 - 71 2085.52 2085.06 c) 
55 - 71 1813.34 1813.93 c,d) 
53 - 78 2790.28 2790.35 e) 
55 - 78 2519.17 2519.22 d,e) 
79 - 163 9620 a) 9622.7 d) 
164 - 192 3326.63 3326.80 c,d) 
193 - 275 8212.5 a,b) 8212.5 c,f) 
276 - 286 1106.76 1106.53 c) 
287 - 314 2593.67 2593.15 
a) linear ToF mass spectrum 
b) used for internal calibration 
c) C-terminal homo-Ser lactone 
d) mild acid cleavage of Asp-Pro bond 
e) C-terminal homo-Ser 
f) N-terminal pyro-Glu 
Next, we were checking if the internal tryptic peptides that were recorded in the 
peptide mass fingerprints were all falling within the estimated sequence ranges 
in order to substantiate the sequence assignments. As an example, the ion 
signal at m/z 1079.33 was assigned to belong to peptide aa 79-88 (Fig. 5). This 
peptide was cleaved by BrCN at Met78 and by trypsin at Arg88, and therefore 
marked the N-terminus of a BrCN-derived fragment with an apparent mass of 
ca. 15 kDa (band 8; cf. Supplemental Table 1) which, consequently, had to 
extend to a residue beyond Met192 but had to end before Met275. Consistent 
with this rationing, the most C-terminal peptide that could be assigned was the 
tryptic peptide ranging from aa 213-227 (m/z 1377.31). All other tryptic peptides 
were within the sequence borders aa 79-227. Such a fragment may have arisen 
by the BrCN fragmentation of a truncated RA33 that was present even after 
HPLC purification. The precise C-terminal end of this fragment, however, 
remains unassigned.  
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Figure 5: MALDI ToF MS peptide mapping analysis after in-gel trypsin digest of BrCN-derived 
protein fragments from immuno-positive band 8 of the SDS PAGE analysis (cf. Fig. 
4). Peptide ion signals are labeled with m/z values. Matching amino acid sequence 
ranges are shown in parentheses. T indicates ion signals due to trypsin auto-
proteolysis. Matrix: CHCA.  
Comparably, in band 9 an ion signal at m/z 1256.64 marked a peptide that had 
been cleaved after Arg 153 on one side and after Asp 163 (by so-called mild 
acid cleavage) on the other. Mild acid cleavage is a side reaction that takes 
place during BrCN degradation predominantly at Asp-Pro bonds. Hence, this 
peptide marks a C-terminal end of a 12 kDa fragment which, therefore, had to 
start most likely at Pro 55. Pro 55 also marks a “mild acid” cleavage site. The 
calculated average molecular mass for this fragment aa 55-163 is 12,153.6 Da. 
With the same reasoning, BrCN-derived fragments aa 79-192 (Mr (avg.): 
12,931.6) and aa 13-121 (Mr (avg.): 12,239.9) were assumed to be co-migrating 
in this band. As this band was the lightest immuno-positive band, the epitope 
had to be within one of these assigned fragments. 
Similar to the reasoning described above, the sequence range of aa 1-71 was 
assigned to the heaviest band that was immuno-negative (band 10; Fig. 4), 
excluding the N-terminal region as epitope carrying range of RA33. Also, as 
immuno-negative band 11 (apparent molecular mass: 6 kDa, starting with 
aa 164) contained a peptide ion signal for aa 173-184 (m/z 1410), the eptiope 
region in recombinant RA33 was estimated to be situated N-terminally to the 
amino acid residue 163. Taking all information on identified partial sequences in 
all SDS PAGE bands together and aligning this information with the immuno-
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positive fractions from the Western blot analysis (Fig. 4), we deduced the 
epitope region against which the monoclonal anti RA33 antibody is directed to 
be within partial amino acid sequence aa 79-163 of recombinant RA33. 
4.3 BrCN degradation of recombinant RA33, subsequent HPLC, and dot 
blot analysis of the fragment mixture with the monoclonal antiRA33 
antibody 
BrCN-derived RA33 fragments were separated by HPLC yielding in ten major 
fractions that were collected individually (Fig. 6A). Sharp HPLC peaks were 
obtained for early eluting fractions. By contrast, later eluting fractions (e.g. 
fractions 8 and 9) were forming fairly broad signals in the chromatogram, 
indicating that the respective RA33 fragments were eluting from the column 
over an extended period of time.  
 
Figure 6: HPLC and dot blot analysis of BrCN-derived fragments of recombinant RA33. A: 
HPLC chromatogram of protein fragments after BrCN degradation. Numbers 
indicate major fractions that were collected and subjected to mass spectrometric 
analysis and to dot blot analysis, respectively. Detection wavelength: 280 nm. For 
partial sequence assignments of BrCN-derived fragments of recombinant RA33 see 
Table 3. B: Dot blot analysis of the HPLC separated fractions and a blank (negative 
control) as well as the full-length RA33 (positive control). 
Despite their low intensities in the chromatogram, the amount of protein that 
eluted in these fractions was quite significant. Dot blot analysis of all HPLC 
fractions (Fig. 6B) showed that only the BrCN-derived RA33 fragments from 
fractions 8 and 9 were immuno-positive.  
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Mass spectrometric analysis of all HPLC fractions enabled assignment of BrCN-
derived RA33 fragments (Table 2). As an example, the linear MALDI-ToF mass 
spectrum of fragments in HPLC fraction 8 showed strong signals in the mass 
range of m/z 3,000-13,500 (Fig. 7).  
 
Figure 7: MALDI ToF MS analysis of a protein fragment from immuno-positive HPLC fraction 
8 (cf. Figure 6). The spectrum was recorded in linear mode (m/z: 3000–35,000). The 
region from m/z 3000–14000 is shown. Peptide ion signals are labelled with m/z 
values. Matching amino acid sequence ranges are shown in parentheses. For 
complete assignments cf. Table 3. M indicates matrix adducts. Matrix: DHB. 
The ion signal at m/z 12,931 was assigned to the partial sequence aa 79-192 
(calculated: 12,931.6 Da) and the ion signal at m/z 9620 to the partial sequence 
aa 79-163 (calculated: 9621.7 Da). The matching doubly charged ion signals 
were observed at m/z 6467 and m/z 4812, respectively. Another strong ion 
signal at m/z 3329 matched with amino acid sequence aa 164-192 (calculated: 
3326.80 Da), showing that peptides with partial sequences starting from aa 79 
up to aa 192 co-eluted in this fraction. 
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Table 2: MALDI MS analysis of RA33 fragments after BrCN cleavage and HPLC separation. 
Fraction No. Exp. Mass (m/z) Calc. Mass [M+H]+; (Da) Sequence Range 
1 1503.67 1503.63 b) 1–12 
2 2593.27 2593.15 287–314 
 3700.60 3700.90 c) 276–314 
3 2593.10 2593.15 287-314 
 3701 a) 3700.9 c) 276–314 
 3747 a) 3747.9 d) 276–314 
4 3326.12 3326.80 b,e) 164–192 
 3346 a) 3346.9 e,f) 164–192 
5 5894 a) - - g) 
 5949 a) - - g) 
 6006 a) - - g) 
 6063 a) - - g) 
6 2085.64 2085.06 b) 53–71 
 2470.75 2471.2 b,c,e,) 55–78 
 2789.71 2790.35 f) 53–78 
 3327 a) 3326.8 b,e) 164–192 
  8229 a) 8230.5 b) 193–275 
 9318 a) 9318.7 b,c,h) 193–286 
7 2085.70 2085.06 b) 53–71 
  2518.25 2519.17 e,f) 55–78 
  2789.04 2790.35 f) 53–78 
  8212 a) 8212.5 b,h) 193–275 
8 2085.70 2085.06 b) 53–71 
 3326.45 3326.80 b,e) 164–192 
 3344.33 3344.80 e,f) 164–192 
 9620 a) 9622.7 e) 79–163 
 12931 a) 12931.6 b) 79–192 
 10279 a) 10280.5 c,e) 72–163 
 10324 a) 10326.5 d,e) 72–163 
 13636 a) 13638.4 f) 72–192 
 13590 a) 13590.4 c,f) 72–192 
9 4812 a) 4814.5 b) 13–52 
  6343 a) 6348.1 b) 1–52 
a) linear ToF mass spectrum 
b) C-terminal homo-Ser lactone 
c) conversion of internal Met residue to homo-Ser without cleavage 
d) oxidation of internal Met residue 
e) mild acid cleavage of Asp-Pro bond 
f) C-terminal homo-Ser 
g) not assigned 
h) N-terminal pyro-Glu 
Taking all information on identified partial sequences in all HPLC fractions 
together (Table 2) and aligning this information with the immuno-positive 
fractions from the dot blot analysis (Fig. 6B), we deduced that the epitope 
region against which the monoclonal antiRA33 antibody is directed to be within 
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the partial amino acid sequence aa 79-163 of the recombinant RA33. This result 
is matching exactly with that from the epitope mapping experiments coming 
from SDS PAGE in combination with Western blot analysis (see above). 
4.4 Peptide chip analysis of synthetic RA33 peptides with monoclonal 
antiRA33 antibody and epitope assignment 
Peptide chips contained synthetic 15-mer peptides of RA33 isoforms listed as 
entries P22626, P09651, and Q99729 in the UniProt database (NP_002128 and 
NP_112533 in NCBI RefSeq). A frame-shift of 6 amino acid residues was 
chosen, resulting in 59 peptides by which the full-length protein sequences were 
represented on the chip surface without redundancies. The monoclonal 
antiRA33 antibody used in this study showed strong signals with mean values 
above 10,000 units for 15 of the 9176 individual peptides on the chip (Table 3).  
Table 3: Epitope motif alignment of 15-mer peptides probed on chip with monoclonal 
antiRA33 antibody. 
No. 15-mer Peptide Sequence a,b,c) UniProt d) Peptide Chip Signal e) 
1         KDSRA.IIRENEFSFE     Q12873 51616 
2   VTYTGDKDSRA.IIRE           Q12873 31042 
3          DSRA.IIRENEFSFED    Q12873 13758 
4    TYVGDKDSRA.IIREN          Q14839 15760 
5    LLESYIDGR..IV.EGSD        P00734 46237 
6  MAARPHSIDGR...VVEP          P22626 36655 
7        SIDGR...VVEPKRAVAR    P22626 10355 
8      TFGCDGRMD..SQQVWD       Q76LX8 39532 
9 EQFLDGDGWTSR..WI.E           P27797 42260 
10       DGWTSR..WI.ESKHKSD     P27797 40728 
11       MDSYSRFEIVGENTR        Q13247 21138 
12 f)          STR.P...EKFLGDIEVWD P26639 16094 
13 f)      STRPEKFLGDI.EVWD        P26639 16094 
14          YGP.P.I.ENGFYYDMYL  P26639 16272 
15    YGGCLCYGP.P.I.ENGF        P26639 10885 
16     WGMEYKGYLVSV.DGY         P62306 60143 
a) GLAM2 program: http://bioinformatics.org.au/glam2/ 
b) Residues printed in bold are part of the consensus sequence 
c) Underlined sequences are from RA33 
d) Protein accession number from UniProt data base 
e) Mean values from triplicate measurements  
f) two alternative alignments for the same 15-mer sequence 
Within these 15 best scoring peptides two were from RA33. The GLAM2 
algorithm21 was applied to search for common motives in the 14 sequences. 
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The best matching motif that coincides on recombinant RA33 with high 
homology to the other sequences that are immuno-positive on the chip is 
DGRVVE.  
In fact, the sequence motif analysis suggests that the epitope peptide consists 
of three parts The N-terminal partial motif consists of three amino acids that 
may be described as “acidic/polar–small–basic” which is best represented by 
the partial sequence “DSR”. The C-terminal partial motif is more promiscuous 
and contains the properties “hydrophobic–gap–acidic”. This motif is best 
represented by the partial sequence “I_E”. The gap between these partial 
motives is up to three amino acids in length. The resulting consensus sequence 
is “DSR (_) I_E”. The consensus peptide is between 7 to 9 amino acids long, 
matches with known sizes of B-cell epitopes. 
The 15mer peptide that belonged to the RA33 sequence with the highest value 
in the chip measurements was covering the range from aa 78-92 
(MAARPHSIDGRVVEP: signal intensity 36,655; Table 4), followed by a peptide 
which covered the adjacent C-terminal sequence range aa 84-98 
(SIDGRVVEPKRAVAR: signal intensity 10,355). Both peptides share the 9 
amino acid long sequence SIDGRVVEP.  
Table 4: Epitope peptide chip results. 
Sequence Range Partial Sequence Mean Signal intensity SD 
        
78-92 MAARPHSIDGRVVEP 36655 13078 
84-98 SIDGRVVEPKRAVAR 10355 2409 
72-86 AEVDAAMAARPHSID 1684 264 
It should be noted that the underlined RA33 partial sequence correlates very 
well with the consensus sequence “DSR (_) I_E”. The peptide that is recognized 
as third best from the RA33 sequence on the chip surface is N-terminally shifted 
(range aa 72-86) and does not contain the amino acids from the consensus 
sequence. The recorded signal for this peptide is, accordingly, much lower 
(signal intensity 1684). All other peptides from the RA33 sequence on the chip 
resulted in even lower signals in the chip measurements. Hence, it can be 
concluded that the epitope for the monoclonal antiRA33 antibody is consisting 
of the amino acid residues SIDGRVVEP that comprise the range aa 84-92 of 
RA33. This result is well in agreement with the BrCN fragmentation experiments 
described above.  
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5. Discussion 
It has been predicted that in the coming decades, proteomics technologies will 
broaden our understanding of the underlying mechanisms of the roles of 
autoantigens in autoimmune diseases and will further our ability to diagnose, 
prognosticate and treat such autoimmune diseases22. Common knowledge 
states that epitopes on proteins were mostly conformational23. However, 
translating the information on conformational epitopes into methods for 
screening of patients in a “cost-effective” manner has been found complicated. 
Whole protein microarrays have still been difficult to produce and to handle10,24. 
Clearly, the use of peptide chips is more robust than using chips with 
immobilized proteins and provides several advantages for clinical purposes. 
Peptides are easily synthesized in a standardized, reproducible, and cost-
effective manner, they can be covalently and specifically attached (including 
spacers or any chemical modification) with nearly equal number of molecules 
per spot, and peptide microarrays are rather stable. Hence, for diagnostic and 
prognostic means it seems more suitable to focus on “peptide-sized” epitopes 
that are recognized by autoantibodies from patients10, whenever this was 
possible. One prime example for peptide-based diagnostics is the use of so-
called “CCP-assays” (cyclic citrullinated peptides) for diagnosing RA25. 
The epitope mapping approach described here is demonstrating that epitope 
sequences which are detected by peptide chip analysis can also be determined 
on full-length proteins. While this seems trivial to state it is important to 
demonstrate this fact experimentally, as autoantibody profiling through epitope 
peptide chip analysis relies on the correlation between screening results and 
the pathological situation of an individual. Without analyzing the epitope on the 
full-length protein the use of peptide chips bears the general problem of 
potentially studying so-called "cryptic" epitopes. Cryptic epitopes are antibody-
binding regions that appear as binding surfaces when partial sequences and not 
the full-length proteins are exposed to antibodies. These antibody bindings have 
to be distinguished from cross-reactivities26,27 that may occur when antibodies 
bind to other full-length proteins, leading to false positive results. Obviously, 
epitope determination on the full-length antigen is required and powerful mass 
spectrometric epitope mapping approaches for analyzing antibody binding 
structures including conformational epitopes have been described. Mass 
spectrometry-based epitope identification methods involve epitope excision28-33 
and epitope extraction34-39. This set of methods may be summarized, together 
with methods in which immunosorption steps have been integrated into mass 
spectrometric analysis as “affinity mass spectrometry”40-42. Epitope extraction is 
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the proteolytic digestion of the free antigen and presentation of the mixture of 
peptide fragments to the antibody (mostly a monoclonal antibody), followed by 
isolation of the antibody-peptide complex. The epitope and non-epitope 
fractions are analyzed by mass spectrometry, and the epitope sequences are 
identified directly. In our experiments the mass spectrometrically determined 
epitope-carrying peptides where ca. 80 aa residues in length and as such too 
large for describing the binding surface only, which for antibodies is estimated 
to be ca. 10 to 12 aa. Several reasons may cause loss of signal intensity by 
Western blot and also to dot-blot analyses. Short peptides are difficult to 
capture on blot membranes and, therefore, may escape detection. Also, 
cleavage of the epitope peptide at the binding site may also cause loss of 
recognition when the epitope is split into two halves. In order to avoid these 
expected adverse effects, we decided to use BrCN for cleavage. BrCN leads to 
larger protein fragments as the distribution of methionine residues in general is 
scarce as compared to that of e.g. lysine and arginine residues. The lack of 
spatial resolution was compensated by adding peptide chip analysis. 
As mentioned, epitope profiling should ultimately serve important clinical 
purposes including classification of individual patients and determining subsets 
of patients based on their “epitope profile”, examination of epitope spreading 
and antibody isotype usage, discovery and characterization of candidate 
autoantigens, and tailoring antigen-driven therapy. The fact that even a 
monoclonal antibody can give rise to multiple signals on a peptide chip 
underlines the importance of thorough studies on epitope structures / 
sequences and binding interactions between (auto)antibodies and 
(auto)antigens. Cross-reactivities of antibodies may be important with respect to 
disease development. 
As can be seen in the 3D structure model of recombinant RA3343-45, the epitope 
which is recognized by the monoclonal antibody is exposed on the surface of 
the protein (Fig. 8). As the part of the protein where the epitope is located has 
been crystallized (PDB structure: 1HA1; hnRNP A1) and also has been studied 
by NMR (PDB structure: 1X4B; solution structure of domain I in hnRNP A2/B1), 
we can visualize the epitope as a -sheet–hairpin–-sheet structure with high 
accuracy. As of yet the 3D structure of the full-length RA33 protein has not been 
published. 
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A 
 
B 
Figure 8: Structural model of recombinant RA33. The three-dimensional structure 
representation has been modeled using the “I-TASSER” algorithm 
(http://zhang.bioinformatics.ku.edu/I-TASSER). A: The ribbon diagram shows -
sheet (arrows), -helices (spirals), and loops (threads). B: The molecular surface is 
indicated with van-der-Waals spheres. The three domains and the N-terminal His-
tag are circled. Sequence ranges are given in parentheses. Residues shown in 
black mark Methionines. The arrow points to the epitope region on the surface of the 
RA33 structure. 
When analyzing the partial sequences from the 15 best scoring peptides 
obtained by peptide chip analysis, the gap between the here described partial 
motives “DSR” and “I_E” was in most cases up to three amino acids in length. 
However, in one case (entries 12 and 13 in Table 3) there are indications that 
there might even be a larger loop possible between the antibody binding spots 
presented on a 15-meric peptide. The binding motif: –STR-(PEKFLGD)-I_E-
VWD would be a matching alternatively to the listed binding motives. Whether 
such a binding conformation was really occurring during the chip analysis - 
perhaps as a result of so-called “induced fit” - or if it was present in a mixed 
situation with other possible (weaker) binding structures remains an open 
question. In general, it seems difficult to define a binding motif (the epitope) as 
being strictly “linear” in almost any case.  
Concerning our studies it is of interest that antiRA33 autoantibodies may appear 
shortly after the onset of rheumatoid arthritis before a final diagnosis can be 
made. Therefore, they can provide diagnostic help in early disease, particularly 
when the RF is negative. In a single case, the presence of the antiRA33 
antibody even preceded disease symptoms by approximately one year5. The 
importance of RA33 in the development of RA and associated disease models 
has been substantiated in recent animal model studies that have shown the 
increase of hnRNP A2 (RA33) abundance in joints of animals with erosive 
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arthritis as a result of increased TNF alpha expression. This overexpression of 
hnRNP A2 correlated with the presence of antiRA33 autoantibodies in these 
animals46, suggesting that the expression of hnRNP A2/B1 and/or the presence 
of the autoantibodies directed against this protein may enhance the 
inflammatory and destructive process. In agreement with this assumption it was 
reported that pristane induced arthritis (PIA) in rats resulted in increase of 
antiRA33 autoantibodies, here preceding onset of the disease47. Again it has 
been suggested that hnRNP A2/B1 is among the primary inducers of 
autoimmunity in PIA, and possibly in RA.  
In conclusion, as autoimmune diseases are chronic inflammatory diseases 
whose development, progression, and recurrence are frequently difficult to 
diagnose48, improving our knowledge in diagnostic or prognostic procedures 
constitutes a research and development area of strategic importance.  
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8. Supplemental Material 
Supplemental Table 1: Masses and sequence coverage of peptide fragments in bands (1-13) 
after BrCN degradation, SDS PAGE separation, and in-gel tryptic digest. 
Band No. a) Exp. Mass (m/z) Calc. Mass [M+H]+; (Da) Sequence Range 
    
1 997.72 996.43 277–286 b) 
31 kDa 1085.71 1087.48 120-128 
(1 – 286) 1377.49 1377.63 213-227 
 1409.89 1410.69 173-184 
 2780.28 2782.27 1-21 
2 997.68 996.43 277–286 b) 
30 kDa 1377.64 1377.63 213-227 
(13-286)    
3 1377.64 1377.63 213-227 
29 kDa 1410.70 1410.69 173-184 
(13-275) 1879.98 1879.96 113-128 
 1927.02 1927.02 21-37 
4 1013.42 1013.44 203-212 
26 kDa 1087.75 1087.48 38-45 
(13-192+X´) 1188.61 1188.64 137-146 
 1377.75 1377.63 213-227 
 1695.77 1695.76 153-167 
 1410.69 1410.69 173-184 
 1879.97 1879.96 113-128 
 1927.01 1927.02 21-37 
5 912.37 912.37 228-237 
25 kDa 1013.42 1013.44 203-212 
(72-314;  1121.54 1121.56 13-20 
13-192+X´´) 1188.63 1188.64 137-146 
 1191.66 1191.55 190–199 c) 
 1249.64 1249.66 13-21 
 1338.67 1338.70 99-111 
 1377.63 1377.62 213-227 
 1410.69 1410.69 173-184 
 1538.79 1538.77 173-185 
 1695.77 1695.76 153-167 
 1879.97 1879.97 113-128 
 1927.01 1927.02 21-37 
 2008.05 2008.06 112-128 
 2433.26 2433.26 152-172 
 2868.34 2867.39 22-45 
 3039.44 3039.48 112-136 
6 1188.44 1188.64 137-146 
20 kDa 1410.36 1410.69 173-184 
(13-192) 1695.98 1695.76 153-167 
 1852.10 1851.87 152-167 
 1879.48 1879.97 113-128 
 2007.55 2008.06 112-128 
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Band No. a) Exp. Mass (m/z) Calc. Mass [M+H]+; (Da) Sequence Range 
7 1079.68 1079.56 79-88 
18 kDa 1188.62 1188.64 137-146 
(79-192+X´; 1410.69 1410.69 173-184 
13-163) 1695.98 1695.76 153-167 
 1852.11 1851.87 152-167 
 1879.99 1879.97 113-128 
 1927.03 1927.02 21-37 
 2008.08 2008.06 112-128 
8 1079.33 1079.56 79-88 
15 kDa 1188.40 1188.64 137-146 
(79-192+X´´) 1377.31 1377.63 213-227 
 1410.36 1410.69 173-184 
 1695.96 1695.76 153-167 
 1852.09 1851.87 152-167 
 1879.55 1879.97 113-128 
 2007.64 2008.06 112-128 
9 1079.33 1079.56 79-88 
12 kDa 1087.22 1087.48 38-45 
(79-192; 1188.34 1188.64 137-146 
55-163 1256.64 1256.51 153–163 d) 
13-121) 1410.88 1410.69 173-184 
 1412.81 1412.62 152-163 d) 
 1879.44 1879.97 113-128 
 1926.49 1927.02 21-37 
 2007.54 2008.06 112-128 
 2185.63 2185.24 79-98 
10 1087.42 1087.48 38-45 
8 kDa 1927.02 1927.02 21-37 
(1-71)    
11 1087.43 1087.48 38-45 
6 kDa 1410.66 1410.69 173-184 
 1927.02 1927.02 21-37 
    
12 1927.01 1927.02 21-37 
5 kDa    
    
13 1927.02 1927.02 21-37 
3.5 kDa    
a) apparent molecular masses are given and estimated sequence ranges of predominant 
fragment(s) are indicated in parentheses 
b) C-terminal homo-Ser lactone 
c) conversion of internal Met residue to homo-Ser without cleavage 
d) mild acid cleavage of Asp-Pro bond 
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1. Abstract 
As the potential of epitope chips for routine application in diagnostics relies on 
the careful selection of peptides, reliable epitope mapping results are of utmost 
interest to the medical community. Mass spectrometric epitope mapping in 
combination with peptide chip analysis showed that autoantibodies from 
patients who suffered from Rheumatoid Arthritis (RA) were directed against 
distinct surface structures on the full-length human autoantigen RA33 as well as 
against partial sequences. Using the combined mass spectrometric epitope 
extraction and peptide chip analysis approach, four sequence motifs on RA33 
emerged as immuno-positive, showing that epitopes were not randomly 
distributed on the entire RA33 amino acid sequence. A sequential epitope motif 
(245GYGGG249) was determined on the C-terminal part of RA33 which matched 
with the Western blot patient screening results using the full-length protein and, 
thus, was regarded as a disease-associated epitope. Other epitope motifs were 
found on N-terminal partial sequences (59RSRGFGF65, 111KKLFVG116) and 
again on the C-terminal part (266NQQPSNYG273) of RA33. As recognition of 
these latter three motifs was also recorded by peptide chip analysis using 
control samples which were negative in the Western blot screening, these latter 
motifs were regarded as "cryptic epitopes". Knowledge of disease-associated 
epitopes is crucial for improving the design of a customized epitope peptide chip 
for RA and mass spectrometric epitope mapping pivotally assisted with 
selecting the most informative peptide(s) to be used for future diagnostic 
purposes. 
Keywords 
Rheumatoid Arthritis; Patient sera, RA33 autoantigen; Epitope mapping; Mass 
spectrometry; MALDI ToF MS; Peptide Chip analysis; Autoimmune diagnostics. 
Abbreviations 
CHCA: -cyano-4-hydroxy-cinnamic acid 
DHB: 2,5-dihydroxy-benzoic acid 
RA33: rheumatoid arthritis autoantigen 33 
TBS: TRIS buffered saline 
ACN: acetonitrile 
BrCN: cyanogen bromide 
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2. Introduction 
RA33 (hnRNP A2/B1) was determined to be a major autoantigen in RA patients 
(prevalence is ca. 35 %), but patients with systemic lupus erythematosus (SLE; 
23 %) and mixed connective tissue disease (MCTD; 39 %) have been found to 
also possess autoantibodies against RA33 1. Recently, it was suggested that 
antiRA33 autoantibodies in patients may be directed against different epitopes 
and that the recognition pattern was associated with the disease 2. Truncated 
recombinant RA33 protein derivatives and RA33-derived synthetic peptides 
were tested with patient sera for immuno-positive reactions and lead to the 
conclusion that RA patients´ autoantibodies against RA33 recognized an 
assembled, i.e. a conformational epitope that was placed on domain II 3. The 
presence of (auto)antibodies against sequential epitopes on RA33 in RA patient 
sera has as yet not been addressed. By contrast, it was found that antiRA33 
autoantibodies from SLE patients were predominantly directed against a 
sequential, i.e. a linear epitope of RA33 comprising aa155-175 2. Hence, 
characterizing the epitope recognition specificities of autoantibodies in addition 
to the determination of the presence of autoantibodies against full-length 
antigens in autoimmune patients´ sera is regarded to be extremely helpful to 
improve the diagnostic and even prognostic value of a screening method which 
may guide individual therapy and on which therapy-related decisions may be 
based on. 
Mass spectrometric and other epitope mapping procedures have become of 
tremendous importance for both, the identification of epitopes on known 
autoantigens and the estimation of cross-reactivities of antibodies with different 
antigens due to related epitope structures 4, 5. Mass spectrometry-based epitope 
identification methods involve epitope excision 5, 6 and epitope extraction 
procedures 7, 8 9-11. In our case, the epitope and non-epitope peptide fractions 
were analyzed by immuno-analytical methods, such as Western blot, and the 
epitope-containing sequences were identified directly by mass spectrometry. 
Our approach made use of the epitope extraction procedure 4 with sera from 
patients that contained polyclonal (auto)antibodies in conjunction with analyzing 
immuno-response of patient sera with peptide chips.  
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3. Patients, materials and methods 
3.1 Patient samples and screening for antiRA33 autoantibodies 
Twenty-four serum samples from 22 patients collected from the Rheumatology 
Clinics Vogelsang, University of Magdeburg, Germany, were included in this 
study (Table 1). The study was approved by the Institutional Review Board and 
blood samples were taken after informed consent was given. All 24 serum 
samples were investigated for the presence of autoantibodies against RA33 by 
Western-blot analysis as described 4. Serum samples are used without further 
purification as used in other clinical and immunological screening assays. 
Recombinant RA33 was expressed in E. coli at the Euroimmun AG, Luebeck, 
Germany.  
3.2 BrCN degradation of recombinant RA33, fragment separations, and 
immuno-analytical determinations 
The BrCN-derived fragments of RA33 4 were loaded onto 4-20 % TRIS glycine 
gels and separated by SDS-PAGE. Western Blot analysis was performed as 
described 4 using serum samples from patients 5 and 11 as antiRA33-antibody 
containing agents. Protein containing bands were manually excised and gel 
plugs were subjected to in-gel digestion with trypsin 12. MALDI-ToF MS 
measurements were performed using a Reflex III mass spectrometer (Bruker 
Daltonik, Bremen, Germany) equipped with the SCOUT source and operated in 
positive ion reflector mode 13. 
The BrCN-derived fragments of RA33 were separated using the HPLC system 
as described 4 on an UltraSep ES PEPTID 125 x 2 mm column. For dot blot 
analysis lyophilized and HPLC-separated fractions of BrCN-derived fragments 
of RA33 were re-dissolved and dot blotted in triplicate using the MINIFOLD 
blotting device (Schleicher & Schuell/Whatman, Dassel, Germany) together with 
intact RA33 as a positive control and a blank (water) as a negative control 4. 
Sera samples from patients 5 and 11 where used as antiRA33-antibody 
containing agents. 
The HPLC-separated and lyophilized BrCN-derived fragments of RA33 were re-
dissolved in 80 % ACN/0.1 % TFA. For MALDI ToF mass spectrometry in linear 
(matrix: saturated ferulic acid solution suspended in aqueous ACN/0.1 % TFA 
33/67 v/v) as well as in reflector mode (saturated CHCA solution suspended in 
aqueous 35 % ACN/0.1 % TFA) sample (0.5 μl) and matrix solutions (0.5 μl) 
were added onto a stainless steel target and left to crystallize on air.  
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3.3 Peptide Chip Analysis 
Replitope™ high density microarrays included peptides from RA33 autoantigen 
isoforms (heterogeneous nuclear ribonucleoprotein hnRNPA2/B1 RefSeq 
Accessions NP_002128 and NP_112533 (P22626)) as well as from hnRNPA1 
(RefSeq NP_002127, NP_112420 (P09651)) and hnRNPAB (RefSeq 
NP_112556, NP_004490 (Q99729)) 4, 14. Here, the chips were used to 
characterize the epitope binding profiles of sera against RA33 from patients 1, 5, 
11, 13, and 24. To each patient sample set a matching "buffer-control" was 
recorded, i.e. buffer instead of patient serum was incubated on the chips. 
Strong signals in the buffer-control originated from secondary antibody binding 
and the respective peptides were excluded from the analysis. As background 
weak signals were regarded. Sample signal intensity was divided by 
background signal intensity for each peptide in order to classify response of 
antibodies (0, X, XX, XXX) to the respective motifs. 
 
4. Results 
4.1 Patient Screening 
Twenty four serum samples from 22 patients were included in the study. All 
patients, except patient 3, were suffering from Rheumatoid Arthritis (RA) as was 
diagnosed by clinical means (e.g. disease activity score (DAS) and X-ray scan) 
and was substantiated by laboratory examinations (e.g. C-reactive protein 
(CRP)). From these samples we identified those RA patients that carried 
autoantibodies against RA33 by Western blot analysis using recombinantly 
produced RA33 (Table 1). The results showed that three from the 24 tested 
patient samples contained antiRA33 autoantibodies. Serum samples of the 
patients that were tested positive by Western blot screening (patients 1, 5, and 
11) were subjected to further analyses (see below). 
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Table 1: Clinical and laboratory data of blood samples and results of Western blot analysis of 
RA patients. 
Sample 
No. 
Gender 
 
Age a) 
[a] 
ESR b) 
[mm/h] 
DAS 28 c) 
 
CCP (GA) d) 
[U/ml] 
CRP e) 
[mg/l] 
Anti-RA33 
Western blot 
1 female 48 / 47 55 4.8 2096 156.2 pos. j) 
2 female 42 / 37 14 2.9 < 25 27.0 neg. 
3 male f) 45 / n.d. g) 11 n.d. g) < 25 < 5 neg. 
4 female 53 / 48 26 6.0 1689 < 5 neg. 
5 male 71 / 62 27 n.d. g) 28 11.3 pos. j) 
6 female 64 / 59 52 5.6 2238 54.8 neg. 
7 female 49 / n.d. g) 20 n.d. g) 45 n.d. g) neg. 
8 female 67 / 59 54 5.1 2036 55.0 neg. 
9 female 62 / 60 30 4.1 < 25 6.1 neg. 
10 female 45 / 32 n.d. g) 6.0 141 8.8 neg. 
11 female 37 / 26 65 7.2 403 107.0 pos. j) 
12 female 61 / 50 6 4.4 < 25 < 5 neg. 
13 female 49 / 28 34 6.3 > 3200 < 5 neg. j) 
14 female 38 / 25 10 3.1 1307 < 5 neg. 
15 female 68 / 64 64 5.1 2318 91.0 neg. 
16 female 50 / 44 110 6.4 186 84.0 neg. 
17 female 51 / 35 55 6.2 < 25 94.0 neg. 
18 male 30 / 29 63 6.8 < 25 112.0 neg. 
19 male 38 / 37 37 5.1 < 25 < 5 neg. 
20 female 41 / 13 50 6.5 < 25 50.0 neg. 
21 female h) 61 / 54 26 6.3 < 25 84.0 neg. 
22 female h) 62 / 54 56 5.9 < 25 81.0 neg. 
23 female i) 42 / 33 n.d. g) n.d. g) < 25 7.9 neg. 
24 female i) 43 / 33 24 7.4 < 25 7.9 neg. j) 
a) age of patient at time point of sample collection/at disease onset  
b) ESR: erythrocyte sedimentation rate  
c) DAS: disease activity score  
d) CCP: anti-“cyclic citrullinated peptide”-antibody conc.; lower threshold: 25 
e) CRP: C-reactive protein; lower threshold: 5 
f) Psoriasis arthritis 
g) n.d.: not documented 
h) same patient,different time point of sample collection 
i) same patient, different time point of sample collection 
j) sample used for peptide chip analysis 
 
In order to identify sequence regions on recombinant RA33 that contained 
epitopes against which the autoantibodies of the patients´ samples were 
directed, we generated RA33 fragments by BrCN degradation of the full-length 
protein and subjected these to epitope mapping experiments. 
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4.2 Mass spectrometric epitope mapping 
4.2.1 SDS-PAGE, mass spectrometric peptide mapping, and Western 
blot 
The BrCN-derived fragments of RA33 were first separated by SDS-PAGE. 
Colloidal Coomassie blue staining revealed that the RA33 protein was cleaved 
completely and 13 protein bands were generated which migrated to 
distinguishable positions in the gel with lower apparent molecular masses than 
that of the starting material (Figure 1A).  
 
Figure 1: SDS PAGE and Western Blot analysis of BrCN-derived fragments of recombinant 
RA33. The SDS-PAGE image is aligned to the matching Western Blot image. A: 1D 
SDS PAGE. Lane 1: Full-length RA33. Lane 2: Bands of BrCN-derived fragments of 
RA33. Molecular mass marker positions are indicated on the left (numbers refer to 
apparent masses in kDa). Bands of BrCN-derived fragments are numbered 
beginning from the top. Major sequence ranges of recombinant RA33 that are 
displayed in the gel bands according to mass spectrometric peptide mapping 
analysis. B: Western Blot analysis using patient sera. Lane 1: Immuno-positive 
bands due to the reaction of the BrCN-derived fragments with serum from patient 5. 
Lane 2: Immuno-positive bands with serum from patient 11. Numbering of immuno-
positive bands is printed in bold letters.  
Mass spectrometric analysis of in-gel tryptic digested peptides from each band 
lead to the assignment of the sequence ranges that were present in the 
respective fragments.  
A typical example is given for the analysis of the BrCN-derived fragments in 
band 5 (see below). In the MALDI ToF mass spectrum of the tryptic peptides 
from the RA33 fragment in band 5 (cf. Figure 1A) a peptide ion signal at m/z 
1121.54 was assigned to the peptide ranging from aa13-20 of the full-length 
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RA33 sequence (Figure 2). Similarly, a peptide ion signal at m/z 1249.64 was 
assigned to peptide aa13-21. Both peptides can be explained by a BrCN 
cleavage at methionine residue 12 (Met12) at the N-terminus and a tryptic 
cleavage at the C-terminus at arginine residue 20 (Arg20) and lysine residue 21 
(Lys21), respectively. Both peptides marked the most N-terminally located part 
of the RA33 fragment in this band. The molecular mass of this RA33 fragment 
in band 5 was estimated to ca. 25 kDa according to its migration behavior in 
SDS-PAGE. Accordingly, the C-terminal end of this fragment was to be located 
above the methionine residue at position 192 (Met192), which marked a 
potential BrCN cleavage site, but below Met275, the next more C-terminally 
positioned cleavage site for BrCN in the sequence. It is well known that during 
BrCN cleavage non-specific degradation may occur, yielding in additional 
fragments, e.g. by so-called "mild-acid" cleavage 15. It was shown independently 
that the recombinant RA33 sample contained truncated protein side products 4 
that may be responsible for the BrCN fragments in band 5 as well. As the 
precise C-terminal end of this fragment has not been determined so far, the 
assignment of the partial sequence of this fragment is given as aa13-X´, where 
the X´ marks a C-terminally located amino acid position beyond the residue 
Met192. Sequence assignments of some of the tryptic peptides were confirmed 
by MS/MS fragmentation (cf. Figure 2). 
 
Figure 2: MALDI ToF MS peptide mapping analysis after in-gel trypsin digest of BrCN-derived 
protein fragments from immuno-positive band 5 (cf. Fig. 1). Peptide ion signals are 
labeled with m/z values. Matching amino acid sequence ranges are shown in 
parentheses. T: ion signals due to trypsin auto-proteolysis; K: ion signals assigned 
to keratin; n.i.: not identified ion signals; *: assignment confirmed by MS/MS peptide 
sequencing. Matrix: CHCA. 
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Additionally, as the tryptic peptide mapping result showed that there are 
peptides which were matching with sequence parts positioned more C-terminal 
than the Met192 residue it was suggested that there might be a mixture of 
peptides co-migrating to the location of band 5 in the gel. The peptide ion signal 
at m/z 1377.63 was assigned to belong to the partial sequence aa213-227. 
From all possibilities to generate an RA33 fragment with ca. 25 kDa in size via 
BrCN cleavage, the best matching partial sequence was assumed to be 
fragment aa79-314 where BrCN had cleaved at Met78. Mass spectrometric 
fragmentation of the peptide with ion signal at m/z 1377.63 (aa213-227) 
resulted in a series of Y" ions and B-NH3 ions that confirmed the partial 
sequence "GGNFGPGPGSNFR" (Figure 3). Hence, the MS/MS sequencing 
results substantiated the assumption that at least two co-migration BrCN-
derived RA33 fragments were present in band 5.  
 
Figure 3: MALDI-QIT-ToF MS/MS spectrum of the ion signal at m/z 1377.63 (cf. Fig. 2). The 
determined partial amino acid sequence is depicted and was assigned to an RA33 
peptide comprising amino acids 213-227. The mass spectrometric fragment ions 
from the Y"-type ion series and the B-NH3-type ion series are indicated. The asterisk 
indicates loss of ammonia. A dot symbol indicates an internal fragment. DHB was 
used as matrix. 
Western blot analysis with sera from patients 5 and 11, respectively, showed 
that the first five BrCN-derived bands stained positive, indicating that epitope(s) 
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were present in these RA33 fragments (Figure 1B). The staining pattern for the 
two tested serum samples was almost identical. Samples from patient 1 were 
not included in this experiment as there was too little sample amount left. As the 
strongly Coomassie stained, immuno-negative band 8 was assigned to contain 
the partial sequence aa79-X´, it was reasoned that the epitope regions for the 
autoantibodies in the tested patient sera were located either N-terminally, i.e. 
within the partial sequence aa13-78, or C-terminal to the (yet undefined) X´ 
position, aaX´-314, of the RA33 sequence (for summarized visualization of the 
results see Figure 6).  
4.2.2 HPLC, mass spectrometric determination of BrCN fragments, 
and dot blot 
In order to verify the results from SDS-PAGE and Western blot experiments we 
performed independent HPLC separations of the BrCN-derived RA33 fragments 
and tested the obtained HPLC fractions for their immuno-analytical behavior 
using dot-blot assays.  
 
Figure 4: HPLC and dot blot analysis of BrCN-derived fragments of recombinant RA33. A: 
HPLC chromatogram of protein fragments after BrCN degradation. Numbers 
indicate major fractions that were collected and subjected to mass spectrometric and 
to dot blot analysis, respectively. Detection wavelength: 280 nm. Partial sequences 
of major BrCN-derived fragments are indicated in parentheses. B: Dot blot analysis 
of the HPLC fractions and a blank (negative control) as well as the full-length RA33 
(positive control). Poorly separated fractions were pooled. Upper panel: sample from 
patient 5. Lower panel: patient 11. 
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Ten HPLC fractions were collected and subjected to mass spectrometric 
analysis 4. In all cases the obtained spectra enabled to assign partial sequences 
of RA33 fragments to the respective fractions (Figure 4A). 
As an example, mass spectrometric analysis of fraction 7 showed the presence 
of peptide ion signals in the low mass range that were assigned to the N-
terminal partial sequence of RA33 around aa53-78 (Figure 5). All observed 
fragments were derived from BrCN cleavage where C-terminal methionine 
residues were turned into homoserine lactone and homoserine residues, 
respectively. In addition, an ion signal that was detected in the high mass range 
at m/z 8212 was assigned to a C-terminal BrCN-derived fragment of RA33 
comprising the partial sequence aa193-275. The peptide assignment is 
consistent with a homoserine lactone residue at the C-terminus and a pyro-
glutamic acid residue at the N-terminus. Conversion of glutamines or glutamic 
acids into pyro-glutamic acids during BrCN cleavage has been described 16. 
 
Figure 5: MALDI ToF MS analysis of a protein fragment from immuno-positive HPLC fraction 
7 (cf. Figure 3). The spectrum was recorded in reflector mode (m/z: 800–3500). The 
linear mode spectrum from m/z 7800–8800 is shown in the insert. Matrix: Ferulic 
acid. Peptide ion signals are labeled with m/z values. Matching amino acid 
sequence ranges are shown in parentheses. 
Dot blot analysis with separated HPLC fractions with autoantibodies from 
patient sera showed that peptides in fraction 8 were giving an intensely stained 
dot. A weaker signal was obtained from peptides in pooled fractions 6/7 when 
compared to the positive control (full length recombinant RA33). The signal 
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intensities in the other fractions only reached background levels (Figure 4B).  
Taking all immuno-staining information from the HPLC fractions together, we 
inferred from these experiments that the epitopes from the autoantigens in the 
tested patient sera (patients 5 and 11) were located in an N-terminal region 
comprising aa53-78 and in a C-terminal region that was located between the yet 
undefined position X´ and Met275 (aaX´-275). This result is consistent with that 
obtained by SDS-PAGE combined with Western blot analysis of the RA33 
fragments but further confined the epitope containing regions (cf. Figure 6; grey 
bars). 
 
Figure 6: Amino acid sequence of RA33 in single letter code. The protein sequence 
resembles the A2 isoform of RA33 (Acc. No. P22626) with a His tag at the N-
terminus (printed in italic letters). The triangle maps the position, where the A2 
isoform of RA33 bears an additional sequence stretch of 40 amino acids that is 
lacking in the recombinant RA33. Methionine residues are underlined. The shaded 
bars indicate the areas which were addressed as epitope carrying regions by mass 
spectrometric epitope mapping. X´ marks a potential location of the yet undefined N-
terminal border of the C-terminal epitope region. The boxes display the epitope 
motifs that are recognized by the antibodies from the patient sera using peptide chip 
analysis (cf. Table 2). 
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4.2.3 Peptide chip epitope analysis 
Additionally, peptide chips were applied for studying interactions of 
(auto)antibodies from patient sera. Here, RA33 partial sequences were 
represented by 15-meric synthetic peptides. The chips were designed such that 
the full-length RA33 sequence was displayed by 59 peptides with a sequence 
overlap of 9 amino acids, each 4. All peptides were present in triplicate, allowing 
to simultaneously collect redundant information as technical replicates. Due to 
the sequence overlap it was possible to acquire redundant information with 
respect to describing epitope sequence motifs. Serum samples from three RA-
positive patients (1, 5, and 11) were analyzed (Table 2) and from patient 11 we 
analyzed three independent serum samples that were collected at different time 
points (samples 11_1, 11_2, and 11_3). These latter samples may be regarded 
as biological replicates. The peptide chip results with these biological replicates 
showed high consistency, emphasizing the robustness of the method. The best 
scoring peptides were used to search over-represented motifs in the most 
significant peptides applying the PRATT Pattern matching tool 17. Four motif 
groups emerged (cf. Figure 6), summarized as epitope motifs 1 (245GYGGG249; 
best fitness: 19.9), 2 (59RSRGFGF65; 24.1), 3 (266NQQPSNYG273; 34.6), and 4 
(111KKLFVG116; 19.0).  
Table 2: Peptide chip analysis of RA33 autoantigen peptides probed with serum samples 
from RA patients a). 
patient motif 1 b) motif 2 c) motif 3 d) motif 4 e) RA33 WB 
 
245GYGGG249 59RSRGFGF65 266NQQPSNYG273 111KKLFVG116  
1 g) X XXX XXX 0 pos. 
5 g) XX XXX XX 0 pos. 
11_1 g) XXX X XX XX pos. 
11_2 g) XXX 0 X XX pos. 
11_3 g) XXX X X X pos. 
13 0 XX X XXX neg. 
24 0 XX XX XX neg. 
a) 0 = signal less intense than 3x that of control 
 X = signal at least 3x more intense than that of control 
 XX = signal at least 10x more intense than that of control 
 XXX = signal at least 20x more intense than that of control 
b) motif is present in 6 of the 19 best scoring peptides out of 5 chips 
c) motif is present in 5 of the 19 best scoring peptides out of 5 chips 
d) motif is present in 3 of the 19 best scoring peptides out of 5 chips 
e) motif is present in 3 of the 19 best scoring peptides out of 5 chips 
f) full length RA33 
g) peptide chip was used to select best scoring peptides 
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Autoantibodies from patient 11 showed strong signals with epitope motif 1 and 
less intense signals for the epitope motifs 2, 3, and 4. Hence, it can be 
concluded that the amino acid sequence 245GYGGG249 represents a dominant 
sequential RA33 epitope in this patient. The same epitope motif was also 
recognized by autoantibodies from patients 1 and 5 with somewhat lesser 
intensities on the chips. Epitope motifs 2 and 3 displayed stronger signals with 
the latter two patient samples whereas there was no detectable response with 
epitope motif 4 (Table 2).  
It is important to note that from the entire RA33 amino acid sequence only four 
short peptide motifs emerged as epitopes by peptide chip analysis. This result 
indicated (i) that epitopes were not randomly distributed on the protein 
sequence, and (ii) that common epitopes were shared between patients. 
However, on top of the common epitope recognition a "patient specific" pattern 
of epitope binding could be observed by the peptide chip analyses as well.  
We also studied the peptide chip responses with (auto)antibodies from RA33-
negative RA patients as controls, i.e. patients whose sera did not give positive 
responses in Western blot analyses using the full-length RA33 (cf. Table 1). 
Interestingly, epitope motifs 2-4 yielded in response signals due to binding of 
antibodies from these sera to the respective peptides. This indicated that these 
epitope motifs might be regarded as so-called "cryptic" epitopes, as the 
respective sequence ranges were not recognized by the patients´ 
(auto)antibodies when displaying the full-length protein. In summary, only motif 
1 was recognized by (auto)antibodies from RA33-positive patients (cf. Table 1) 
and, hence, remained the only epitope motif that correlated with both, the mass 
spectrometric epitope mapping results and the Western blot results obtained 
with the full-length recombinant RA33.  
In order to estimate surface accessibility of the discussed epitope motifs on the 
full-length RA33 protein we mapped the epitope sequences on a 3D model of 
recombinant RA33 (Figure 7). 
 
 
 
 
 
 
 
Eur. J. Mass Spectrom. (2010) 16, 443-451 
 
66 
[A] 
 
[B] 
 
Figure 7: Structural representations of recombinant RA33. The three-dimensional structure 
representation has been modeled using the “I-TASSER” algorithm 
(http://zhang.bioinformatics.ku.edu/I-TASSER). The molecular surface is indicated 
with van-der-Waals spheres. The His tag region is displayed in black, domain I in 
yellow, domain II in blue, and domain III in green. A: The epitope-containing regions 
as determined by mass spectrometry are shown in red. B: The four epitope motifs 
as derived form the peptide chip analysis are displayed in red and are circled. 
Sequence ranges of the motifs are given.  
The model made use of a partial tertiary structure that encompasses the two N-
terminal domains of a related protein (protein data base entry: 1HA1). The third 
domain (C-terminal domain) was modeled on top of this structure using the I-
TASSER program 18, 19. Interestingly, epitope motifs 1 and 3 appeared well 
accessible on the surface of domain III (co-localizing with the mass 
spectrometrically defined epitope-containing region X´-275). However, as no 
crystal structure of domain III is available, the actual surface areas of the 
epitope motifs 1 and 3 cannot be determined. Motifs 2 and 4 seemed fairly 
buried in domain I and in domain II, respectively (Figure 7). It should be noted 
that the mass spectrometrically derived epitope-containing partial sequence 53-
78 encompassed motif 2 on domain I but not motif 4 on domain II.  
 
5. Discussion 
The aim of our studies was to emerge a disease-associated epitope pattern that 
ultimately shall enable to stratify patients for selecting the best available therapy 
for each individual. Mapping of epitope regions on (auto)antigens using patient 
sera that contained polyclonal (auto)antibodies should result in the assignment 
of more than one epitope on a given (auto)antigen, when these polyclonal 
(auto)antibodies are directed against different surface structures of the 
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(auto)antigen under study. Hence, detection of four major epitope motifs on 
RA33 against which (auto)antibodies from patient sera are directed is, at first 
hand, not surprising.  
The existence of epitopes in the C-terminal region of RA33 against which 
autoantibodies from RA patients were directed has been mentioned 1. However, 
distinct epitopes in that region have not yet been defined. It is of importance to 
note that the C-terminal regions of RA33 were mostly neglected in earlier 
epitope identification analyses 2, 3, 20, 21. Instead, focus had been laid onto N-
terminal epitope regions.  
Our combined mass spectrometric epitope extraction and peptide chip analysis 
approach specifically addresses sequential epitopes (named linear or 
continuous epitopes in many literature references). The simultaneous presence 
of (auto)antibodies directed against structurally assembled epitopes (also 
termed conformational or discontinuous epitopes) on an (auto)antigen is not 
ruled out.  
A general issue to be addressed in epitope mapping experiments with truncated 
partial proteins or peptides is the recognition of partial structures by the 
(auto)antibodies that are displayed only when parts of the full-length molecule 
are absent. In these cases the recognition of so-called "cryptic epitopes" has to 
be considered 4. Cryptic epitope responses should not match with analysis 
results from assays (e.g. Western blot) in which the full-length protein is used. 
As a consequence, presenting surface-bound peptides to patient sera (bottom-
up approach) should be accompanied by epitope determination strategies that 
start out with the full-length antigen (top-down approach). Comparison of the 
results from the two independent approaches is recommended for interpreting 
epitope mapping data.  
Epitope extraction describes the proteolytic digestion of the free antigen and 
presentation of the mixture of peptide fragments to the antibody under 
investigation, followed by isolation of the antibody-peptide complex from which 
the epitope-containing peptide is liberated prior to analysis 4-8. The 
simultaneous preparation of the epitope peptide bound antibody complex 
directly on the MALDI target has also been demonstrated by using monoclonal 
antibodies 9, 10.  
It should be noted that three of the four peptide chip-derived epitope motifs fell 
within the regions that were assigned as epitope carrying partial sequences 
from the mass spectrometric epitope mapping analysis (cf. Figure 6). This 
showed that BrCN-derived fragments of RA33 also displayed "cryptic" epitopes 
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in addition to so-called "disease-associated" sequential epitopes. The 
corroborated information seems crucial when aiming at epitope-based 
screening applications for diagnostics. 
For patient screening purposes the application of peptide chips seems more 
robust and less error prone than the use of full-length antigen arrays 14. The use 
of epitope chips eliminates all potential cross-reactivities that are always of 
concern with full-length autoantigens that may give rise to false positive 
reactions. Therefore, the goal of this study was to identify such epitope peptides 
that are disease-associated. Whether epitope chips shall assist or even replace 
antigen-based diagnostic assays in the future relies on the experiences that 
shall be made with respect to specificity and sensitivity of these assays, i.e. 
false positive and false negative rates. The ultimate performance of a peptide 
chip in this respect certainly relies on the careful selection of peptides, 
catapulting reliable epitope mapping results into the center of interest.  
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1. Abstract 
The development and application of a mass spectrometry-based epitope 
mapping procedure in solution and without immobilization of the antibody is 
described. Antigens were digested with proteases. Then size exclusion micro-
column chromatography (SEC) was carried out prior to and upon exposure of 
the peptide mixtures to monoclonal antibodies. The epitope-containing peptide, 
affinity bound to the antibody and, thus, forming a stable complex eluted early 
as did all high-mass components, whereas all unbound low-mass peptides 
eluted late. Comparison of elution profiles in the presence and absence of the 
antibody showed a shift only for epitope-bearing peptides, enabling direct 
identification of the epitope. His-tag containing recombinant antigens Fibrillarin 
and RA33 were used in combination with an anti-His-tag monoclonal antibody in 
order to develop the method. Application of the method for the determination of 
an epitope on RA33 against which a monoclonal antibody was directed 
identified the epitope sequence (85IDGRVVEPKRA95) using MS/MS peptide 
sequencing. Advantages of this approach include low sample consumption, few 
handling steps, and short duration of analysis. With our method we are 
ultimately aiming at developing a screening procedure to identify major epitopes 
in patients that may be suitable in the future for stratification of patients, needed 
for personalized therapies. 
Keywords 
epitope mapping, epitope extraction, enzymatic proteolysis, size exclusion 
chromatography, matrix assisted laser desorption/ionization mass spectrometry, 
monoclonal antibody 
 
Abbreviations 
aa: amino acid, DHB: 2,5-dihydroxy benzoic acid, RA33: rheumatoid arthritis 
auto-antigen33, ACN: acetonitrile, TFA: trifluoroacetic acid, NH4HCO3: 
ammonium bicarbonate, TBS: tris buffered saline, BSA: bovine serum albumin 
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In-solution epitope mapping 
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2. Introduction 
Epitope mapping is the process of identification of the molecular determinants 
for antibody–antigen recognition on the antigen. Identification of the epitope is a 
key step in the characterization of monoclonal antibodies, especially those used 
in therapeutic strategies (Nelson et al., 2000). It has also been essential in the 
design of vaccines against toxins (Kazemi and Finkelstein, 1991; Logan et al., 
1991) or against enzymes (Gonzalez et al., 1994; Saint-Remy, 1997). To obtain 
information on sequential and/or assembled epitopes, various approaches have 
been developed in conjunction with mass spectrometry (Suckau et al., 1990; 
Hager-Braun and Tomer, 2005). Fine epitope mapping could be achieved by 
this approach with microgram quantities of antibodies and in a short time 
compared to conventional mapping methods (Dhungana et al., 2009; Macht et 
al., 1996; Parker et al., 1996; Suckau et al., 1990). The epitope analysis can be 
performed by epitope excision (Juszczyk et al., 2009; Hager-Braun et al., 2006; 
Hochleitner et al., 2000; Suckau et al., 1990; Przybylski, 1994) or by epitope 
extraction (Tian et al., 2007; Bílková et al., 2005; Zhao et al., 1996; Zhao and 
Chait, 1994). In both cases the method is based on the fact that antibodies in 
general are very resistant to proteolytic digestion whereas the antigen has to be 
readily degradable. 
In epitope excision studies, mass spectrometry was used to identify epitope 
peptides released from an immobilized antibody-antigen complex after limited 
proteolysis (Pimenova et al., 2009; Parker and Tomer, 2002; Suckau et al., 
1990). Here, the antibody prevents either proteolysis (Jemmerson, 1996) or 
chemical modification (Burnens et al., 1987) of sites of the antigen that are 
situated in the antibody binding pocket. However, because of the steric 
hindrance between bound antibody and proteolytic enzyme, the determined 
region is generally larger than the protected epitope that is recognized by the 
antibody as binding site (Manca, 1991). An important feature of this approach is 
that, because non-denaturing conditions are used, the antigen retains its native 
conformation so that assembled (conformational) epitopes can be determined 
(Parker and Tomer, 2000). 
In epitope extraction, a protease digested antigen peptide mixture is in most 
cases affinity-bound to an immobilized antibody. The epitope peptides are 
analyzed by MALDI-MS after washing off all unbound peptides and upon 
release of the epitope peptide from the immobilized antibody. Subsequently, 
sequential (linear) epitopes are identified directly by mass spectrometry (Bílková 
et al., 2005; Parker and Tomer, 2002). 
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In both approaches the peptides containing the epitopes are dissociated from 
the immobilized antibodies by elution with low pH buffer. The high accuracy and 
sensitivity of mass spectrometry helps in identifying the peptides that are 
regarded as epitopes. Furthermore, the resulting antibody-peptide complex 
must survive all procedures and washing steps prior to release of the epitope 
peptides. These mass spectrometry based methods in general require that the 
antibody be immobilized prior to reaction with antigen. Also critical to the 
success of this method is the choice of the proteolytic enzyme by which the 
antigen is being degraded and the already mentioned given stability of the 
antibody against proteolysis.  
In contrast to the procedure described above, an alternative epitope extraction 
procedure without immobilization of the antibody was described where epitope 
peptides were identified from a direct comparison of the MALDI mass spectra of 
the peptide control mixture with that following interaction with antibody. 
Disappearance of peptide ion signals in the mass spectra from the antibody 
reaction mixture was interpreted as a result of antibody-binding to the epitope 
sequences within the protein (Kiselar and Downard, 1999). 
Our study presents a simplified approach that maps the epitope on a given 
antigen also without immobilization of the antibody and without a separate step 
to dissociate the epitope peptide from the antibody-peptide complex prior to 
mass spectrometric analysis. The antigen-antibody complex is maintained in 
solution throughout all steps needed for separating epitope-containing peptide 
from all non-binding peptides affinity bound to the antibody using size-exclusion 
chromatography. As size exclusion chromatography is a method readily applied 
to the analysis of intact molecular weights of antibodies and antibody 
conjugates (Brady et al., 2008; Lazar et al., 2005) the overall handling 
procedure is simple and straight forward. In contrast to previous reports, 
dissociation of the epitope peptides from the antibody occurs simultaneously to 
the preparation of the peptides for MALDI-MS analysis with acidic matrices. Our 
novel epitope mapping approach was developed using a model system 
consisting of a commercially available monoclonal antibody directed towards 
the His-tag sequence present in recombinant Fibrillarin and RA33 proteins. Our 
method was further applied successfully to a known system composed of a 
monoclonal antibody directed towards its sequential epitope on RA33 (El-Kased 
et al., 2009). 
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3. Materials and methods 
3.1 Proteins and antibodies 
Recombinant Fibrillarin protein derivative comprising amino acid range 76-321 
of the full-length protein was a gift from the Institute of Immunology, University 
of Rostock, Germany. The protein was obtained in solution consisting of 50 mM 
sodium phosphate, pH 8, 0.3 M sodium chloride, 0.05% Tween 20 and 8 M urea, 
with a protein concentration of 1.21 mg ml-1.  Microcon® centrifugal filter devices 
YM-10 [Millipore, USA] were used to desalt and concentrate the protein solution 
according to the manufacturer`s protocol. 300 μl of protein solution were 
rebuffered and concentrated to a protein concentration of 2.25 mg ml-1 in 
ammonium bicarbonate buffer, pH 8.5. The solution was then aliquoted (30 μl 
each) and stored at -20 ºC. Recombinant RA33 protein was purchased from 
Euroimmun AG, Luebeck, Germany. This autoantigen was shipped in solution 
consisting of 50 mM sodium phosphate, pH 7.4; 8 M urea; and 1000 mM 
sodium chloride, with a protein concentration of 2.42 mg ml-1. 100 μl protein 
solution were quantitatively precipitated using 400 μl methanol/100 μl 
chloroform solution and resolubilised in 1000 μl 3 mM TRIS/HCl, pH 8.5, then 
aliquoted (30 μl each) and stored at -20 ºC. Penta-His antibody was purchased 
lyophilized from QIAGEN® GmbH [Hilden, Germany]. The lyophilized antibody 
(100 μg) was dissolved in 100 μl distilled water resulting in a protein 
concentration of 1 mg ml-1. Anti-Histidine tag monoclonal antibody was 
purchased from AbD Serotec [Düsseldorf, Germany] in a phosphate buffered 
saline, pH 7.4, with a protein concentration of 1 mg ml-1. Anti-RA33 monoclonal 
antibody (mouse anti-hnRNP-A2/B1) was purchased from Sigma [Munich, 
Germany]. The antibody was in solution consisting of 0.01 M phosphate 
buffered saline, pH 7.4, and 15 mM sodium azide, with a protein concentration 
of 1.5 mg ml-1. 
3.2 Proteolytic digests 
Recombinant protein aliquots, dissolved in 30 μl of buffer (see above), were 
reduced with 3 μl 0.1 M freshly prepared dithiothreitol solution (15 mg DTT 
powder dissolved in 1 ml distilled water) at 56 ºC for 30 min. Subsequently, 
freshly prepared iodoacetamide solution (6 μl; 18.5 mg IAA powder dissolved in 
1 ml distilled water) was added at room temperature and incubated in the dark 
for 30 min in order to alkylate sulfhydryl groups. For in-solution tryptic digest, an 
enzyme solution of 1 mg ml-1 in 3 mM TRIS/HCl, pH 8.5 was used [Promega, 
Madison, WI, USA]. 1.35 μl and 1.45 μl, respectively, enzyme solution were 
added. Enzyme:substrate ratio was 1:50. In both experiments digestion was 
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incubated overnight at room temperature. For in-solution thermolytic digest; an 
enzyme solution of 1 mg ml-1 in sodium acetate buffer, pH 8.5 was used [Sigma, 
Munich, Germany]. 1.45 μl enzyme solution were added to 30 μl RA33 solution 
with enzyme:substrate ratio of 1:50. The mixture was incubated overnight at 
room temperature. 
3.3 Incubation of proteolytic peptide mixtures derived from antigens with 
antibody prior to size exclusion 
66.7 pmol anti-His antibody were incubated overnight at room temperature in 
two separate experiments with 17.5 pmol tryptic digest peptide mixture derived 
from Fibrillarin and 17.5 pmol tryptic digest peptide mixture derived from RA33, 
respectively. 100 pmol monoclonal antibody were incubated overnight at room 
temperature with 35 pmol thermolytic digest peptide mixture derived from RA33. 
3.4 Size exclusion chromatography of proteolytic peptides in the 
presence of the antibody 
1 ml pipette tip (1000 μl blue tip, Greiner Bio-one GmbH, Frickenhausen, 
Germany) was used as a microcolumn. First, a small filter paper [MoBiTec, 
Goettingen, Germany] was inserted manually to act as a frit. Second, 250 μl of 
the gel slurry [Superdex 30; GE Healthcare] were added after vigorous shaking. 
After precipitation of the gel, the supernatant was pushed through and 
discarded. Such prepared tips were first washed with 100 μl water and then 
equilibrated with 100 μl of the elution buffer. 50 mM ammonium bicarbonate, 
pH 8.5 [Fluka, Germany] and 10% ACN/0.1% TFA, pH 2.2, respectively, were 
used as elution buffers. All solutions were loaded onto the top of the 
microcolumn using a pipette and the liquid was pressed through the 
microcolumn using an air-filled plastic syringe. For peptide elution, 10 μl of 
sample were loaded and allowed to enter the column bed. Next, 10 μl of elution 
buffer were loaded and gently pushed through the column, generating fraction 1. 
This procedure was repeated with addition of 10 μl of buffer each, until 10 
fractions were collected in total.  
3.5 SDS PAGE analysis  
5 μl of sample were mixed with 5 μl two-fold tricine SDS sample buffer 
containing 100 mM Tris-HCl, pH 6.8, 0.3 % SDS, 24 % glycerol (w/v), 8 % SDS 
(w/v), 5 % 2-mercaptoethanol (v/v) and 0.02 % Bromophenol Blue (w/v). This 
sample solution (10 μl) was loaded onto a 16 % tricine gel, 1.00 mm x 10 well 
[Invitrogen, Karlsruhe, Germany]. The Broad Range Marker [New England 
BioLabs, Frankfurt/Main, Germany] as well as the Ultralow Range Marker 
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[Sigma, Munich, Germany] were used for determining apparent molecular 
masses of the protein bands. Gels were run in tricine SDS running buffer (1M 
Tris, 1M tricine, 1% SDS) (Schägger et al., 1988), using the Xcell SurelockTM 
MiniCell electrophoresis chamber [Invitrogen, Karlsruhe, Germany] at a 
constant voltage of 125 V for 60 min. Gels were fixed with a 50 % ethanol/10% 
acetic acid/water solution and stained with colloidal Coomassie Brillant Blue G-
250 (Neuhoff et al., 1988).  
3.6 Western blot and Dot blot analysis 
For Western blot analysis; 1D SDS PAGE was performed. Protein bands were 
blotted onto a PVDF membrane [Immobilon, Millipore, Schwalbach, Germany] 
by semi-dry blotting for 60 min with a current of 1.2 mA/cm2. The membrane 
was cut into strips. After blocking the strips with 2 ml blocking buffer (TBS 5 % 
non-fat dry milk powder, 1 % BSA 0.02 % thimerosal) for 2 h, one RA33 protein 
strip was incubated with the monoclonal antibody (1:1900) over night at 4 °C. A 
second RA33 protein strip and a Fibrillarin protein strip were incubated with the 
anti-His antibody (1:1900) overnight at 4°C.  Washing (three times, in TBS, 
0.05 % TWEEN 20 (v/v), 0.1 % BSA (w/v), 0.02 % thimerosal (w/v)) was 
followed by secondary antibody reaction (biotin-GAH IgG + IgM anti-mouse, 
1:20,000, Jackson Immuno Research Laboratories, Inc., West Grove, PA, 
USA/Dianova) for 1 h at room temperature. Another washing step and reaction 
with streptavidin peroxidase (1:10,000, Jackson ImmunoResearch Laboratories, 
Inc., West Grove, PA, USA/Dianova) was carried out for 1 h at room 
temperature. Detection was performed using the SuperSignal West Pico 
Chemiluminiscent substrate [Pierce/ThermoFisher Scientific, Bonn, Germany]. 
Images were electronically processed to enhance band patterns. 
For dot-blot analysis, fractions were collected after size exclusion 
chromatography of a mixture of the monoclonal antibody that was incubated 
with thermolysin. The MINIFOLD blotting device [Schleicher & Schuell/ 
Whatman, Dassel, Germany] was used and an antibody sample prior to elution 
was used as a positive control. After dot blotting, the membrane was taken out 
of the device and blocking as well as antibody incubation was performed as 
described above. 
3.7 Mass spectrometry 
For mass spectrometric peptide mapping, 0.5 μl of the sample solution were 
spotted on a stainless steel target (Bruker Daltonik, Bremen, Germany) and 
0.5 μl of DHB matrix solution (12.5 mg/ml in 50 % ACN/0.1 % TFA) were added 
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and mixed with the sample solution directly on the target. The mixture was then 
allowed air-dry. MALDI ToF MS measurements were performed using a Reflex 
III mass spectrometer [Bruker Daltonik, Bremen, Germany] equipped with the 
SCOUT source and operated in positive ion reflector mode. MALDI was carried 
out utilizing a nitrogen pulsed laser (337 nm, 3-5 ns pulse width). A total of 400 
laser shots were accumulated producing sum spectra ranging from m/z 800–
3500. Spectra were externally calibrated with a commercially available Peptide 
Calibration Standard [Bruker Daltonik, Bremen, Germany] then analyzed using 
FlexAnalysis 2.4 program [Bruker Daltonik, Bremen, Germany]. MS/MS spectra 
were acquired with an Axima MALDI QIT ToF mass spectrometer [Shimadzu 
Biotech, Manchester, UK] in positive ion mode utilizing a nitrogen pulsed laser 
(337 nm, 3-5 ns pulse width) and employing a three-dimensional quadrupole ion 
trap supplied by helium (pulsed flow gas) for collisional cooling and argon 
(collisional gas) to impose collisionally induced dissociation (CID) (Koy et al., 
2003; Koy et al., 2004). Spectra were externally calibrated with a manually 
mixed peptide standard consisting of bradykinin (1-7) [M+H]+ 757.39, 
angiotensin II [M+H]+ 1046.53, angiotensin I [M+H]+ 1296.68, bombesin [M+H]+ 
1619.81, N-acetyl renin substrate [M+H]+1800.93, ACTH (1-17) [M+H]+ 2093.08, 
ACTH (18-39) [M+H]+ 2465.19, somatostatin [M+H]+ 3147.46, insulin (oxidized 
beta chain) [M+H]+ 3494.64. Further processing and analysis of the MS/MS 
spectra was performed with the LaunchpadTM software, version 2.7.1 [Shimadzu 
Biotech, Manchester, UK]. 
 
4. Results 
In order to develop and to apply our mass spectrometry-based epitope mapping 
procedure without immobilization of the antibody we investigated two 
recombinant proteins, Fibrillarin and RA33, for which monoclonal antibodies 
with different binding specificities were commercially available. As a prerequisite 
for the study we first checked antibody binding to the respective full-length 
antigen by Western blot. The recombinant proteins Fibrillarin and RA33 showed 
strong bands at apparent masses of 29 kDa and 33 kDa, respectively, showing 
the decoration of the full-length proteins with the respective antibodies [Figure 
1].  
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Figure 1: Western Blot analysis. Lane A: Immuno-positive band at 29 kDa apparent molecular 
mass shows the full length recombinant Fibrillarin protein decorated with anti-His 
antibody. Bands at 26 kDa and 24 kDa, respectively, show truncations. Lane B: 
Immuno-positive band at 33 kDa apparent molecular mass shows the full length 
recombinant RA33 protein decorated with anti-His antibody. Lane C: Immuno-
positive band at 33 kDa apparent molecular mass shows the full length recombinant 
RA33 protein decorated with monoclonal anti-RA33 antibody. Molecular mass 
marker positions are indicated on the left (numbers refer to apparent molecular 
masses in kDa). 
Fibrillarin, when stained by the monoclonal anti-His-tag antibody, showed also 
faint bands for truncated forms whereas RA33 staining was producing single 
bands. All band locations in the Western blot were in agreement with SDS-
PAGE analyses of the full-length proteins [cf. Figure 2].  
 
Figure 2: SDS-PAGE of recombinant proteins before and after enzymatic proteolysis. [A] 1D 
SDS-PAGE of recombinant Fibrillarin protein. Lane 1: full length protein. Lane 2: 
band of trypsin-truncated Fibrillarin. [B] 1D SDS-PAGE of recombinant RA33 protein. 
Lane 1: full length protein. Lane 2: band of trypsin proteolysis products of RA33 are 
encircled. [C]: 1D SDS-PAGE of recombinant RA33 protein. Lane 1: full length 
protein. Lane 2: bands of thermolysin proteolysis products of RA33 are encircled. 
Molecular mass marker positions are indicated on the left (numbers refer to 
apparent molecular masses in kDa). 
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Next, in-solution proteolytic digests were performed in order to generate peptide 
mixtures, ideally with (all) peptides possessing molecular masses below 
5,000 Da. These mixtures should contain the epitope sequences together with 
other non-epitope-containing peptides from the same protein or from other 
(contaminating) proteins in the sample, e.g. derived from impurities that may 
come from the expression systems. The success of the proteolysis reactions 
was monitored by both, SDS-PAGE [Figure 2] and mass spectrometric peptide 
mapping [Supplemental figures 1, 2, and 3].  
In-solution trypsin digest of Fibrillarin resulted in partial proteolysis where the 
resulting peptide mixture showed incomplete digestion with a remaining protein 
band at approx. 24 kDa in the gel [Figure 2A] and with a singly charged 
molecular ion at m/z 23,603 in linear MALDI ToF MS [data not shown], 
indicating that Fibrillarin is quite resistant to proteolysis.  
Nevertheless, in mass spectra ranging from m/z 775 to m/z 2520 [Table 1; 
Supplemental Figure 1] plenty of peptide ion signals were observed, resulting in 
nearly complete sequence coverage of recombinant Fibrillarin [cf. Figure 3D].  
Table 1: MALDI MS analysis of Fibrillarin peptides after tryptic digest. 
Sequence range [M+H]+ calcd m/z (exp.) 
3-27 2676.20 2676.16 
35 - 42 981.49 981.49 
35 - 50 1979.97 1979.98 
43 - 50 1017.49 1017.49 
53 - 59 775.42 775.42 
60 - 71 1291.65 1291.63 
73 - 85 1510.74 1510.74 
86 - 91 790.40 790.43 
94 - 112 1872.11 1872.13 
113 - 145 3416.75 3416.67 
149 - 155 786.47 786.47 
158 - 168 1240.69 1240.67 
175 - 194 2233.14 2233.10 
195 - 205 1254.73 1254.73 
206 - 215 1071.59 1071.57 
216 - 234 1969.92 1969.91 
216 - 235 2098.01 2098.01 
235 - 254 2520.22 2520.17 
236 - 254 2392.13 2392.10 
255 - 268 1533.85 1533.87 
255 - 270 1761.02 1761.91 
As mass spectrometric peptide mapping showed that peptides were produced 
that covered nearly the entire sequence of Fibrillarin, we considered this mixture 
suitable for further investigations using size exclusion chromatography despite 
the fact that digestion was incomplete.  
J. Proteomics Bioinform. (2011) 4, 001-009   
 
 
81 
By contrast, tryptic digestion of RA33 resulted in complete proteolysis where the 
resulting peptide mixture showed ion signals in the mass range between m/z 
800 and m/z 3000 [Table 2; Supplemental Figure 2] leading to nearly full 
sequence coverage [cf. Figure 4D]. Accordingly, SDS PAGE showed faint and 
diffuse bands with maximal apparent masses of approx. 4 kDa [Figure 2B]. 
Table 2: MALDI MS analysis of RA33 peptides after tryptic digest. 
Sequence range [M+H]+ calcd (Da) m/z (exp.) 
15-20 836.43 836.70 
15-21 964.52 964.78 
21-37 1927.02 1927.45 
22-37 1798.92 1799.33 
38-45 1087.48 1087.72 
46-53 993.49 993.73 
46-58 1491.73 1492.07 
62-88 2827.33 2827.95 
99-111 1338.70 1338.96 
112-119 861.56 861.81 
112-128 2008.06 2008.50 
113-128 1879.97 1880.39 
120-128 1165.52 1165.78 
129-136 1050.44 1050.68 
129-146 2220.07 2220.10 
137-146 1188.65 1188.90 
152-167 1851.87 1852.27 
152-172 2433.26 2433.77 
153-167 1695.76 1696.13 
153-172 2277.16 2277.66 
173-184 1410.69 1411.02 
173-185 1538.78 1539.13 
186-199 1648.81 1648.20 
190-199 1221.55 1221.84 
200-212 1313.60 1313.87 
203-212 1013.44 1013.70 
213-227 1377.63 1377.94 
228-237 912.38 912.63 
277-284 781.36 781.61 
285-309 2189.91 2190.37 
Comparably, in-solution thermolysin digestion of RA33 resulted again in 
complete proteolysis of the starting material where the resulting peptide mixture 
showed ion signals in the mass range between m/z 600 and m/z 3000 [Table 3; 
Supplemental Figure 3], also leading to nearly full sequence coverage [Figure 
5D]. 
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Table 3: MALDI MS analysis of RA33 peptides after thermolytic digest. 
Sequence range [M+H]+ calcd (Da) m/z (exp.) 
1-12 1551.63 1550.54 
2-12 1420.59 1419.81 
2-19 2367.04 2366.54 
12-21 1380.70 1380.92 
12-26 1867.98 1867.36 
30-36 808.36 808.74 
30-46 2146.01 2146.43 
30-50 2621.18 2621.70 
37-46 1372.67 * 1372.70 * 
46-62 1890.96 1890.88 
50-62 1458.79 1459.57 
51-62 1359.73 1360.73 
52-64 1464.75 1465.69 
53-65 1480.78 1481.64 
57-65 1041.56 1041.68 
65-76 1303.59 1303.74 
80-88 1008.53 1008.78 
85-94 1168.68 1168.50 
85-95 1239.72 1240.01 
96-109 1437.74 1437.79 
96-112 1793 1793.62 
98-110 1366.71 1366.70 
114-130 2044.97 2045.40 
119-127 1137.63 1137.69 
119-131 1718.78 1718.40 
128-137 1319.63 1318.72 
132-142 1309.65 1309.60 
143-155 1449.79 1449.73 
143-156 1596.86 1596.93 
157-167 1287.58 1286.68 
159-164 745.28 745.87 
159-167 1087.47 1086.70 
159-169 1299.62 1299.49 
160-165 697.28 696.81 
160-168 1053.48 1053.31 
169-176 1001.58 1002.25 
171-176 789.43 789.09 
171-181 1282.63 1283.24 
176-186 1208.65 1208.52 
184-192 1118.61 1118.70 
187-205 2106.01 2106.37 
187-207 2310.10 2310.25 
187-217 3214.48 3214.71 
188-206 2139.99 2140.42 
193-208 1712.81 1712.66 
196-206 1152.55 1151.69 
207-218 1127.49 1127.75 
207-226 1840.80 1841.19 
209-218 923.40 924.16 
209-226 1636.71 1637.08 
209-239 2890.26 2889.73 
218-225 732.33 732.26 
219-239 1985.88 1986.24 
227-239 1272.57 1272.72 
263-280 2002.87 2003.44 
280-312 3100.35 3100.89 
280-314 3342.47 3342.67 
286-312 2482.06 2482.02 
286-314 2724.18 2724.79 
* oxidation of tryptophan residue 
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In agreement with mass spectrometry results, SDS PAGE analysis showed faint 
and diffuse bands with maximal apparent masses of ca. 3.5 kDa [Figure 2C]. 
Accordingly, both RA33-derived digest mixtures were found well suitable for 
subsequent size exclusion experiments. 
Size exclusion chromatography with a cut-off of roughly 4 to 5 kDa was applied 
in order to separate high-mass components, such as undigested starting 
material, protease, and, most importantly the antibody in the digest mixtures 
from the low-mass components, i.e. enzymatically produced peptides. 
According to the size exclusion principle, high-mass compounds were expected 
to elute in early fractions (fractions 2 to 5 in our set-up; fraction 1 being the void) 
and low-mass compounds (below 4 to 5 kDa) should be present in late eluting 
fractions (fractions 6 to 10 in our set-up). Each experiment was performed such 
that for control and for investigating the elution profile of the proteolytic peptide 
mixture alone a first set of 10 fractions was collected with a volume of 10 μl 
each. Peptides should only be found in the late eluting fractions. In the second 
set of elution fractions the peptide mixture was first incubated with the antibody 
and for elution the same experimental conditions were applied as mentioned 
above. Hence, a comparable set of 10 fractions was obtained. The major 
difference between the two sets of data should be a shift in migration of the 
epitope peptide. This peptide was expected to be pulled through the column 
when bound to the antibody during filtration, now ending up in an early eluting 
fraction. All fractions from each set were analyzed by MALDI MS in the mass 
range of m/z 800 to m/z 3500. 
For the control experiment with Fibrillarin, as expected, no peptide ion signals 
were observed in mass spectra until fraction 5 (early eluting) [Figure 3B] which 
stands in contrast to the mass spectra that were obtained from higher 
numbered (late eluting) fractions [data not shown].  
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Figure 3: MALDI ToF MS peptide mapping analysis and amino acid sequence of Fibrillarin.  [A] 
MS spectrum range m/z 2500 – 3000 shows Fibrillarin epitope peptide in early 
eluting fraction (3) upon binding to anti-His antibody. [B] MS spectrum of early 
eluting fraction in the absence of anti-His antibody remains empty. [C] MS spectrum 
of tryptic Fibrillarin peptides. [D] Amino acid sequence in single letter code of 
Fibrillarin showing sequence coverage after trypsin digest in bold letters. The 
shaded sequence display the epitope motif that is recognized by the ant-His 
antibody.  Matrix: DHB, n.i: not identified, E: derived from trypsin autoproteolysis, •: 
sodium adduct. 
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The elution behaviour of the epitope containing peptide was different in the 
presence of the monoclonal anti-His antibody during filtration. After incubation 
with the anti-His antibody the epitope peptide appeared in an early eluting 
fraction (fraction 3) [Figure 3A]. This epitope peptide at m/z 2676.16 which was 
absent in the control experiment but observed in the peptide mixture before 
SEC [Figure 3C] was further investigated by MS/MS peptide sequencing and 
determined the amino acid sequence of the His-tag peptide covering the range 
aa 3–27 (3GSHHHHHHGSYLGDTIESSTHASGK27) of recombinant Fibrillarin 
[data not shown] and confirming tryptic cleavage after arginine residue 2 and 
lysine residue 27.  
For RA33 epitope mapping using the monoclonal anti-His-tag antibody, the 
epitope peptide eluted early (fraction 4) together with its methionine-oxidation 
products in the presence of the antibody [Figure 4A]. The epitope peptide at m/z 
2093.13 was found to be covering the sequence range aa 1–16 
(1MSHHHHHHHHSMEREK16). Chemically assisted fragmentation-MALDI (CAF-
MALDI) and subsequent MS/MS measurements were used to confirm the 
sequence assignment [data not shown]. This peptide was completely absent in 
the late eluting fractions after antibody incubation [Figure 4B]. Notably, the 
peptide ion signal was also not detectable in the peptide mixture before SEC 
[Figure 4C]. The absence of the ion signal in the latter two samples can be 
explained by suppression effects and by low ionization yields of the peptide. 
Only in the rather pure early eluting fraction larger ionization yields were 
obtained mounting in sufficient intensity of this peptide ion signal to be 
observable by MS. Again, trypsin was found to cleave the protein after lysine 
and arginine residues according to its known sequence specificity. 
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Figure 4: MALDI ToF MS peptide mapping analysis and amino acid sequence of RA33. [A] 
MS spectrum range m/z 2050–2350 shows RA33 epitope peptide in early eluting 
fraction upon incubation with anti-His antibody. [B] MS spectrum of RA33 peptides in 
late eluting fraction upon incubation with anti-His antibody. [C] MS spectrum of 
tryptic RA33 peptides. [D] Amino acid sequence in single letter code of RA33 
showing sequence coverage after trypsin digest in bold letters. The shaded 
sequence display the epitope motif that is recognized by the ant-His antibody.  
Matrix: DHB, E: derived from trypsin autoproteolysis, •: sodium adduct, : potassium 
adduct, *: oxidation. 
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Since the developed procedure worked well with two different proteins and 
reliably isolated the His-tag peptide as the antibody-bound epitope, we went for 
a first application example and selected a monoclonal antibody that was 
directed against an internal sequence of the antigen RA33. Again, RA33 was 
first digested, this time with thermolysin. Thermolysin is a "non-sequence 
specific" enzyme which preferentially cleaves at the N-terminal side of bulky and 
aromatic residues Ile, Leu, Val, Ala, Met, and Phe (Keil, 1992), but was readily 
applicable in our experiments as it yielded in complete proteolysis, which is 
advantageous when the goal is to determine a specific epitope to the smallest 
number of amino acids residues, as long as the epitope is not destroyed by 
cleavage. The resulting epitope peptide eluted early (fraction 3) in the presence 
of the antibody [Figure 5A]. In the control experiment, i.e. in the absence of the 
antibody during filtration, the same peptide eluted late (fraction 8) together with 
other non-epitope peptides [Figure 5B]. For comparison, the mass spectrum of 
the thermolytic peptide mixture before SEC is shown [Figure 5C]. This epitope 
peptide at m/z 1240.01 was further investigated using MS/MS peptide 
sequencing [Figure 6] which confirmed that the peptide comprised the range aa 
85–95 (85IDGRVVEPKRA95) of RA33. This result stands in agreement with the 
previously assigned epitope using immuno-analytical methods coupled with 
mass spectrometry (El-Kased et al., 2009).  
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Figure 5: MALDI ToF MS peptide mapping analysis and amino acid sequence of RA33. [A] 
MS spectrum range m/z 1100–1500 shows RA33 epitope peptide in early eluting 
fraction upon incubation with monoclonal anti-RA33 antibody. [B] MS spectrum of 
late eluting RA33 peptides in the absence of monoclonal anti-RA33 antibody. [C] MS 
spectrum of thermolytic RA33 peptides. [D] Amino acid sequence in single letter 
code of RA33 showing sequence coverage after thermolysin digest in bold letters. 
The shaded sequence displays the epitope motif that is recognized by the 
monoclonal anti-RA33 antibody. Matrix: DHB, E: derived from thermolysin 
autoproteolysis, : potassium adduct, B: derived from buffer, *: oxidation.  
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Figure 6: MALDI QIT ToF MS/MS spectrum of the ion signal at m/z 1240.01 (c.f Figure 5A). 
The determined partial amino acid sequence is depicted and was assigned to an 
RA33 peptide comprising amino acids 85–95. The mass spectrometric fragment ions 
from the Y type ion series and the B type ion series are indicated. Loss of ammonia 
and loss of water, respectively, is indicated. DHB was used as a matrix. 
The here described experiments were accompanied by control runs in which all 
conditions of the size exclusion chromatography steps were tested in order to 
determine potentially interfering ion signals that may appear in mass spectra 
after elution (i) due to bleeding of the gel slurry during filtration [Supplemental 
Table 1], (ii) due to background signals derived from enzyme autoproteolysis 
during incubation [Supplemental Tables 2 and 3], or (iii) derived from partial 
degradation of the antibodies used in the study [Supplemental Table 4]. The 
generated lists of background signals from these mock experiments were found 
helpful for defining the epitope peptide ion signals in the early eluting fractions 
after subtraction of all potential background signals. 
In the end, the most important criterion for defining the epitope peptide was the 
shift in elution of a peptide upon binding to the antibody so that it was identified 
in the early eluting fraction where otherwise only high mass compounds 
appeared, despite being small enough to elute in late eluting fractions when 
unbound. 
5. Discussion 
Fibrillarin, is a 34 kDa autoantigen, present in all nucleated cell types that 
derives its name from its localization to both the fibrillar center (FC) and dense 
fibrillar component (DFC) of the nucleolus (Ochs RL 1985). As a component of 
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all small nucleolar ribonucleoprotein particles (snoRNPs), Fibrillarin seems to be 
involved in nearly all major post-transcriptional activities in ribosome synthesis, 
the first steps of rRNA processing, pre-rRNA modification, and ribosome 
assembly (Tollervey et al., 1993). Fibrillarin is a target for the spontaneously 
arising auto-antibodies in systemic sclerosis autoimmune disease (Ssc; 
scleroderma) (Takeuchi et al., 1995). Similarly, the RA33 auto-antigen, present 
in rheumatic autoimmune diseases, carries its name according to its migration 
behaviour in sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE), and has been found to be identical to the protein named hnRNP A2/B1 
(RefSeq accessions NP_002128 and NP_112533; Uniprot Accession number 
P22626). HnRNP proteins are associated with pre-mRNAs in the nucleus in 
complex 4 which forms part of the spliceosome (Steiner and Smolen, 2002). 
They are involved in pre-mRNA processing and other aspects of mRNA 
metabolism and transport. It has been reported that the presence of anti-RA33 
antibodies may preceed disease symptoms by one year (Steiner et al., 1996). 
Therefore they can provide diagnostic help early in disease, particularly when 
Rheumatoid factor (RF) is negative in patient samples. In conjunction with anti-
cyclic citrullinated peptide antibody (antiCCP antibody) level determination, 
measuring anti-RA33 autoantibody levels in RA patients and in other 
autoimmune patients has become important in particular for diagnosing RA in 
the absence of RF and for estimating severity of the disease (Feist et al., 2007; 
Steiner and Smolen, 2002). As both proteins play their roles in autoimmune 
diseases it is of interest to identify epitopes to which autoantibodies from 
individual patients are directed. Therefore, epitope mapping approaches that 
are suitable for studying patient sample-derived autoantibodies are of high 
interest.  
The functional integrity of an antibody in all steps of our epitope mapping 
procedure is a prerequisite for successful application. This was checked by dot 
blot analysis with fractions from size exclusion chromatography. Binding of the 
antibody to the antigen was found in early eluting fractions [Supplemental 
Figure 6], showing that the antibody survived the procedure intact and 
biologically active. The widely accepted knowledge that antibodies in general 
are resistant to proteolytic digestion, however, appeared not to be absolute. We 
recommend to check each commercially available antibody by incubation with 
the protease of choice, as in one example the anti-His-tag antibody was partially 
digested generating two dominant peptide ion signals at m/z 1488.73 and m/z 
2383.41 upon incubation with trypsin [Figure 7].  
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Figure 7: MALDI ToF MS spectrum of antibody derived peptides in early fraction after 
incubation with protease. [A] MS spectrum range m/z 750–3500 of the early eluting 
fraction of anti-His antibody after incubation with trypsin. [B] MS spectrum of the 
early eluting fraction of monoclonal antibody after incubation with thermolysin. DHB 
was used as a matrix. 
Both peptides were analyzed further using mass spectrometric peptide 
sequencing and confirmed that the generated peptides were part of the IgG 
heavy chain variable region and of the IgG light chain variable region, 
respectively [data not shown]. The proteolytically nicked antibody subsequently 
lost its capability to bind to its antigen and, hence, was not applicable for 
epitope mapping. By contrast, a different and more robust anti-His-tag antibody 
as well as the monoclonal anti-RA33 antibody proved to be stable against 
proteolysis under the employed conditions and, therefore, both antibodies were 
found suitable for our peptide mapping procedure. 
Preferably for our method, the proteolytic enzyme of choice should produce 
peptides of masses below 4 kDa to ensure a shift in elution upon binding to the 
antibody as compared to the free peptide. At the same time, the presence of 
high-mass compounds do not interfere with the epitope mapping procedure as 
long as they do not contain all of the epitope sequences. This is due to the fact 
that the mass spectrometric measurements were tuned to the (low) mass range 
of interest below m/z 4,000. Because with peptides in that mass range MS/MS 
peptide fragmentation normally can be readily performed using the epitope 
peptides from the early eluting fractions, sequence specificity of the protease is 
not a major concern in epitope mapping using our method.  
Estimating the adequate sample amount is an important step for obtaining 
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reliable results with this size exclusion chromatography-based method. Sample 
overloading leads to the escape of peptides to early fractions. In our approach 
using a sample volume of ca. 4% of the total bed volume and a peptide amount 
up to 35 pmol was found adequate to obtain optimal elution profiles. Our 
experimental procedure shows that incubation at a 3:1 ratio of antibody to 
peptides is well suitable for epitope mapping. This rather fixed antibody/peptide 
ratio differs from those reported in the literature where excess of antibody varies 
in broader ranges (Pimenova et al., 2009; Dhungana et al., 2009; Zhao and 
Chait, 1994) while in other studies peptides were used in excess (Bílková et al., 
2005; Parker and Tomer, 2002; Peter and Tomer, 2001; Kiselar and Downard, 
1999; Papac et al., 1994). 
With our method dissociation of the antigen-antibody complex prior to mass 
spectrometric analysis is unnecessary because dissociation occurs during 
sample preparation of the collected fraction material onto the MALDI target 
simultaneously to the crystallization process of the MALDI matrix, leading to a 
decrease in sample handling and making it suitable for screening purposes in a 
clinical environment. We are ultimately aiming at a screening procedure to 
identify major epitopes in patients that may be suitable in the future for 
stratification of patients. Hence, reproducibility, ease of handling, minimal 
sample consumption as well as robustness of the method, as is the case with 
our method, are of utmost importance. 
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8. Supplemental material 
 
Supplemental Figure 1: MALDI ToF MS analysis of tryptic digest of Fibrillarin. Peptide ion 
signals are labeled with m/z values. Matching amino acid sequence ranges are shown in 
parentheses. E: ion signals due to trypsin enzyme autoproteolysis. A dot symbol indicates 
sodium adducts. Matrix: DHB. 
 
 
Supplemental Figure 2: MALDI ToF MS analysis of tryptic digest of RA33. Peptide ion signals 
are labeled with m/z values. Matching amino acid sequence ranges are shown in parentheses. 
The asterisk indicates oxidation. Matrix: DHB. 
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Supplemental Figure 3: MALDI ToF MS analysis of thermolytic digest of RA33. Peptide ion 
signals are labeled with m/z values. Matching amino acid sequence ranges are shown in 
parentheses. The asterisk indicates oxidation. Matrix: DHB. 
 
 
 
 
Supplemental Figure 4: Dot blot analysis of monoclonal antibody against RA33 after 
incubation with thermolysin and after size exclusion chromatography. Numbers indicate eluting 
fractions.  . C: control reaction with monoclonal antibody without elution. Fractions 1 and 6–10 
show only background staining. 
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Supplemental Table 1: Exclusion list of ion signals observed after size exclusion 
chromatography of buffer solution. 
m/z (exp.) 
868.78 
905.48 
997.43 
1052.32 
1126.36 
1148.83 
1246.93 
1295.81 
1535.76 
1590.23 
1672.14 
1701.28 
1718.31 
1803.36 
1877.30 
1950.44 
1992.49 
2107.56 
2347.50 
2764.47 
 
Supplemental Table 2: Exclusion list of ion signals observed after size exclusion 
chromatography of trypsin autoproteolysis products. 
 
m/z (exp.) 
842.54 
856.48 
984.41 
1020.43 
1044.46 
1189.42 
1432.52 
1446.57 
1607.60 
1621.58 
1940.60 
2210.86 
2224.84 
2238.83 
2845.24 
2928.26 
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Supplemental Table 3: Exclusion list of ion signals observed after size exclusion 
chromatography of thermolysin autoproteolysis products. 
 
m/z (exp.) 
973.37 
1007.40 
1032.46 
1136.45 
1152.45 
1158.46 
1174.32 
1208.55 
1283.55 
1335.65 
1400.67 
1448.75 
1495.68 
1824.95 
1866.90 
1986.58 
2029.96 
2070.46 
2365.33 
 
Supplemental Table 4: Exclusion list of ion signals observed after size exclusion 
chromatography of anti-His antibody incubated with trypsin. 
 
m/z (exp.) 
935.18 
1017.33 
1083.30 
1124.35 
1254.38 
1232.44 
1274.48 
1288.41 
1388.47 
1398.48 
1567.49 
1593.59 
1737.67 
1809.58 
1865.80 
1872.76 
1926.70 
2027.85 
2054.77 
2187.86 
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100 
m/z (exp.) 
2440.86 
2587.97 
2610.05 
2652.05 
2846.09 
3078.25 
3339.49 
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